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The thioredoxin system consisting of thioredoxin, thioredoxin reductase and NADPH plays a 
significant role in a large number of redox-dependent processes including DNA synthesis and 
anti-oxidant defense. Perturbations of this system have been associated with a number of 
diseases but contradictory descriptions of thioredoxin as both an enzyme and a redox couple 
have complicated the quantification of the system in these pathologies with Michaelis-
Menten parameters, activity measurements, redox potentials and redox ratios all being used to 
describe the thioredoxin system in vitro and in vivo. To clarify these discrepancies, the 
thioredoxin system from Saccharomyces cerevisiae was cloned, expressed and purified and 
computational modeling as well as in vitro studies were used to show that accurate parameter 
sets for thioredoxin reduction reactions can be obtained by fitting the thioredoxin system, 
rather than the Michaelis-Menten equation to substrate saturation datasets. It was also 
confirmed that substrate saturation in the insulin reduction assay was due to the saturation of 
the thioredoxin redox cycle caused by limiting thioredoxin reductase concentrations, the 
progressive redistribution of the thioredoxin moiety into its oxidized form or both. Validation 
of this mechanism then enabled the use of computational models of the thioredoxin system to 
identify the minimum, experimentally tractable, parameter set needed to quantitatively 
describe the steady state behaviour of this system under stress conditions. The flux through 
the system represents a comprehensive description of the state of the system, but currently 
there are no methods available to measure this flux in vivo and therefore core and realistic 
models based on the thioredoxin system were used to determine how the existing measures of 
thioredoxin activity corresponded to the flux of the system under reductive supply and 
oxidative demand conditions. Computational modeling using a basic model of the E. coli 
thioredoxin system and comprehensive, in vivo computational models systematically tested 
all of the measures of the Trx system and revealed that a novel measure, the thioredoxin 
redox charge, may be a useful surrogate measure of the flux within the system. This result 
was confirmed by in vitro reductive supply and oxidative demand assays and western blot 
analysis using the reconstituted yeast peroxiredoxin system. Collectively, these results 
propose a novel, independent and experimentally tractable surrogate measure for flux through 
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 The rise in planetary oxygen levels as a by-product of cyanobacterial photosynthesis 
approximately 2.5 billion years ago had a dramatic effect on the development of living 
systems, leading to a massive extinction event which displaced obligate anaerobes as the 
primary life form on the planet (Sessions et al., 2009, Planavsky et al., 2014). This space was 
occupied by aerobic organisms which used oxygen as a terminal electron acceptor in cellular 
respiration and consequently gained a vastly more efficient energy metabolism together with 
novel biochemical pathways. Nonetheless this improved energy metabolism came at a price. 
In a series of classical papers McCord and Fridovich showed that living cells actively 
catalyze the dismutation of superoxide to molecular oxygen and hydrogen peroxide (McCord 
and Fridovich, 1969a, McCord and Fridovich, 1969b, McCord and Fridovich, 1970). The 
development of this assay together with several other assays revealed that living systems 
have evolved a barrage of enzymes and metabolites to protect themselves against the 
damaging effects of oxygen-derived species. This and other work led to the Free Radical 
Theory of Disease in which posited that reactive oxygen species (ROS) were an unavoidable 
consequence of aerobic metabolism and that when present in excess, result in several 
pathologies (Harman, 1956). The use of antioxidant regimens in the prevention and treatment 
of these disease states was therefore widely embraced but clinical studies have since shown 
that antioxidant therapy is associated with accelerated disease progression and other 
detrimental effects (Steinhubl, 2008, Persson et al., 2014, Sayin et al., 2014, Le Gal et al., 
2015).  
 
These studies have revealed the complexity of redox homeostasis with ROS appearing to 
play dual roles as toxins and as essential signalling molecules (Jones, 2006, D'Autreaux and 
Toledano, 2007, Pham-Huy et al., 2008). Aerobic metabolism is now considered a finely 
constructed network with multiple and discrete connections, redox signaling pathways and 
circuits (Jones, 2006). A key mediator in this network is the thioredoxin system composed of 
thioredoxin (Trx), NADP(H), and thioredoxin reductase (Figure 1.1). In this system, 
thioredoxin reductase uses NADPH to reduce thioredoxin, which in turn reduces a wide array 
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of protein and non-protein targets, forming a large redox-regulated network (Collet and 
Messens, 2010, Jones and Go, 2011). This network provides reducing equivalents for key 
cellular metabolic processes including DNA synthesis, antioxidant defense and the regulation 
of redox signal transduction (Arnér and Holmgren, 2000b, Toledano et al., 2007). The 
components of the system will be described below. 
 
 
Figure 1.1 The thioredoxin system. Reduced Trx (TrxSH) directly reduces oxidized 
proteins and is oxidized (TrxSS). The regeneration of Trx from its oxidized form is catalyzed 
by thioredoxin reductase (TR) using NADPH (Lillig and Holmgren, 2007). 
 
1.2 The thioredoxin system 
1.2.1 Thioredoxin reductase  
Thioredoxin reductase is a member of a family of pyridine nucleotide-disulfide 
oxidoreductases (Williams, 1995, Arnér and Holmgren, 2000b). Members of this family are 
homodimeric flavoproteins, in which each subunit has an NADPH binding site, a redox-
active disulfide bond and a tightly bound flavin adenine dinucleotide (FAD) prosthetic group 
(Williams, 1995, Zhong et al., 2000) which mediates the transfer of reducing equivalents 
from NADPH to its own disulfide bond, and then to the disulfide bond of the substrate 
(Holmgren and Bjornstedt, 1995, Williams, 1995). Thioredoxin reductase is responsible for 
the reduction of oxidized Trx and is also able to reduce non-disulfide substrates such as 
hydrogen peroxide albeit at a significantly lower rate than specialized peroxidases (Takemoto 
et al., 1998). 
 
Thioredoxin reductases can be classified into two types, based on size. The first type has a 
higher molecular mass of approximately 55 kDa and is generally found in animals  (Gasdaska 
et al., 1995) and protozoa such as the malaria parasite (Krnajski et al., 2001), and is more 
closely related to glutathione reductase than to bacterial thioredoxin reductase. This reductase 
also has a broader substrate specificity (Mustacich and Powis, 2000) and contains the rare 
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amino acid selenocysteine (Sec) in its active site in place of the conserved cysteine (Cys) 
found in bacterial thioredoxin reductase (Arnér and Holmgren, 2000b, Zhong et al., 2000). 
This Sec residue is essential for the catalytic activity of thioredoxin reductase because either 
its removal (Nordberg et al., 1998) or modification (Gorlatov and Stadtman, 1998, Nordberg 
et al., 1998) leads to inactivation of the enzyme. Sec participates in the reaction mechanism 
of thioredoxin reductase in two important thiol/disulfide exchange reactions; first, the 
selenolate of Sec acts as the electron donor to thioredoxin and second, as part of the 
selenosulfide bond found in the C-terminus of the enzyme, selenium accepts electrons from 
the oxidation of NADPH in the N-terminal redox center of thioredoxin reductase (Lothrop et 
al., 2014).  
 
The second type of thioredoxin reductase is present in archaea, bacteria and eukarya 
including fungi, plants and the protozoan intestinal parasite Entamoeba. This enzyme has a 
lower molecular mass of 35 kDa (Williams, 1995, Hirt et al., 2002) and is related to the alkyl 
hydroperoxide reductase (AhpF) (Poole et al., 2000). There is approximately 20% sequence 
identity between high molecular weight thioredoxin reductase and its low molecular weight 
counterpart in the region where they can be reliably aligned. Further, unlike the high 
molecular weight thioredoxin reductase that has a redox-active centre located in the FAD-
binding domain, the redox-active disulfide of the low molecular weight thioredoxin reductase 
is located in the NADPH domain showing the significant variation between the two types of 
thioredoxin reductase (Hirt et al., 2002). Enzyme catalysis also involves two redox reactions 
with the formation of disulfide bonds following the reduction of Trx and reducing equivalents 
are obtained from NADPH oxidation.   
 
1.2.2 Thioredoxin 
Trx is a low molecular weight (12 kDa), thermostable and ubiquitous protein that can be  
localized in the cytoplasm, nucleus or in mitochondrial cell fractions (Das et al., 1999). The 
key to the redox activity of this protein is the presence of two cysteine residues (Cys32 and 
Cys35) separated by two amino acids (Gly-Pro) in its conserved active site. These cysteines 
exist as a dithiol (-(SH)2) or as a disulfide (-S2) in the reduced and oxidized states, 
respectively. Thioredoxin reductase reduces the disulfide bond forming reduced Trx which 
can then form a complex with an oxidized substrate via a hydrophobic surface patch (Collet 
and Messens, 2010). Upon the formation of this complex, thiol-disulfide exchange generates 
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oxidized Trx and the reduced substrate (Figure 1.2) (Holmgren, 1985) ultimately linking the 
activities of both Trx and thioredoxin reductase.  
 
Figure 1.2 Mechanism by which thioredoxin catalyses the reduction of protein 
disulfides. Reduced thioredoxin (Trx-(SH)2) binds to an oxidized target protein (X- S2) via its 
hydrophobic surface patch. Nucleophilic attack by the thiolate of Cys32 results in formation 
of a transient mixed disulfide, which is followed by a nucleophilic attack of the deprotonated 
Cys35 generating oxidized thioredoxin (Trx-S2) and the reduced protein (X-(SH)2) 
(Holmgren, 1995). (Reprinted with permission from the Elsevier publishing company) 
 
1.3 Connectivity of the thioredoxin system  
The biosynthetic reactions in which Trx has been implicated include providing reducing 
equivalents to ribonucleotide reductase, thioredoxin peroxidase (Pigiet and Conley, 1977),  
methionine sulfoxide reductases (Sengupta and Holmgren, 2012), the regeneration of 
oxidatively damaged proteins and scavenging reactive oxygen species as well as other free 
radicals (Das and Das, 2000). Several transcription factors are also redox regulated by Trx 
which modulates their DNA binding activities and/or their retention within the nucleus 
(Holmgren and Lu, 2010, Karlenius and Tonissen, 2010). In mammalian cells, Trx directly 
modulates the activity of various transcription factors such as AP-1 and p53 (Mukherjee and 
Martin, 2008) while some transcription factors can be indirectly affected by Trx. For 
example, Ref-1 (redox factor-1) is reduced by Trx which in turn activates other redox-
regulated transcription factors that are responsible for the activation of many genes 
responsible for promoting cell viability in response to oxidative stress and hypoxia (Demple 
et al., 1991, Robson and Hickson, 1991, Robson et al., 1991, Hawkes et al., 2014). 
Interestingly, Ref-1 functions not only as a major redox-signaling factor but is also a DNA-
repair endonuclease, and is involved in the base excision repair (BER) pathway which is 
responsible for restoring apurinic/apyrimidinic (AP) sites in DNA, a major end product in 
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reactive oxygen species (ROS) damage (Demple et al., 1991, Hawkes et al., 2014). 
Additionally, Trx plays pivotal roles in the regulation of redox signalling as it senses and 
responds to environmental oxidative stress as well as ROS generated by cellular respiration 
and metabolism. Trx is responsible for modulating the redox state, function, and activity of 
its target signalling proteins. Trx controls the mitogen-activated protein kinase (MAPK) 
cascades through the redox state-dependent association and dissociation with apoptosis 
signal-regulating kinase 1 (ASK1), an upstream regulator of the cascades. In unstimulated 
cells, ASK1 forms an inactive complex with reduced Trx (Fujino et al., 2006). However, 
exposure to ROS causes the oxidation of Trx leading to the dissociation of Trx from ASK1, 
which consequently converts the inactive form of ASK1 to an active kinase (Matsuzawa and 
Ichijo, 2008). Trx also regulates other kinases or components of signalling pathways. The 
phosphatase PTEN functions as a terminator of the Akt signalling pathway which plays a 
central role in cell growth and survival. Trx directly interacts with PTEN inhibiting its 
phosphatase activity and membrane binding resulting in the activation of the Akt pathway 
(Meuillet et al., 2004). 
 
In plants, the thioredoxin system provides a crucial link between the activities of electron 
transport and carbon assimilation (Meyer et al., 2008). Approximately 500 proteins had been 
identified as potential or established Trx targets in land plants and oxygenic photosynthetic 
microorganisms (Montrichard et al., 2009). Plant Trxs are involved in multiple processes 
such as photorespiration, lipid and hormone metabolism, membrane transport, ATP synthesis 
(Balmer et al., 2004) and seed germination (Joudrier et al., 2005). In the chloroplast, the 
activities of a number of enzymes including four enzymes of the Benson-Calvin cycle, 
fructose bisphosphatase, sedoheptulose bisphosphatase, ribulose-5-P kinase and 
glyceraldehyde-3-phosphate dehydrogenase are all regulated by Trx (Dey and Harborne, 
1997). Other chloroplastic enzymes regulated by Trx include NADP-malate dehydrogenase, 
phenylalanine ammonia lyase and glucose-6-phosphate dehydrogenase (Dey and Harborne, 
1997). A Trx isoform, Trx h has been associated in the reduction of seed α-amylase and 
trypsin inhibitors from several sources (Jiao et al., 1992).   
 
In addition to the Trx-dependent reactions outlined above, a large variety of other potential 
substrates that interact intracellularly with Trx have been identified through omic techniques 
and methods. For example, the C-terminal cysteine of the catalytic site of Trx which is 
essential for resolving the mixed disulfide complex that results in the release of a reduced 
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substrate protein and oxidized Trx (Figure 1.2) can be mutated to an alanine (Balmer et al., 
2004) allowing the formation of stable complexes between Trx and its substrates (Depuydt et 
al., 2009). Using this approach in combination with affinity chromatography, 50 potential 
Trx-linked proteins functional in 12 processes including electron transport, transformation, 
translation, protein assembly and folding, were identified from photosynthetic and 
heterotrophic mitochondrial sources (Balmer et al., 2004). 
 
An alternate approach involved the purification of proteins bound to Trx using Tandem 
Affinity Purification (TAP) followed by MS/MS mass spectrometry analysis. The procedure 
involves a TAP-tag being appended to the C-terminus of Escherichia coli Trx1 and thereafter 
the Trx-substrate complexes were purified using two affinity chromatography steps. Using 
this method, a total of 80 E. coli proteins have been identified, implicating Trx1 in 
approximately 26 cellular processes including transcriptional regulation, cell division, energy 
transduction, and several biosynthetic pathways (Kumar et al., 2004).  
 
Another approach to identify Trx substrates involves differential thiol-labeling (Leichert 
and Jakob, 2004). In this approach, accessible thiol groups are carbamidomethylated (CAM) 
with iodoacetamide (IAM) and blocked for the subsequent reduction and alkylation steps. 
DTT is used to reduce the disulfide bonds and the newly accessible thiols are then labeled 
with radioactive iodoacetamide (
14
C-IAM). A radioactive label is therefore incorporated into 
the proteins that originally contained disulfide bonds. Proteins that require Trx for reduction 
can be identified through a comparison of cellular extracts prepared from wild-type and Trx-
knockout strains. Using this approach, a considerable number of redox-sensitive cytoplasmic 
proteins containing significantly oxidized thiol groups were identified in strains lacking 
thioredoxin. These included detoxifying enzymes as well as several metabolic enzymes with 
active-site cysteines that were previously unknown substrates of thioredoxin (Leichert and 
Jakob, 2004). 
 
Thus the thioredoxin system has multiple interactions with several cellular processes 
creating a complex and interconnected redox network. Perturbations of this network have, not 
surprisingly, been correlated with several oxidative stress-associated acute and chronic 
diseases (Figure 1.3).  However, quantifying the contribution of this system in redox 




1.4 Measurement of the thioredoxin system  
Confusingly, a number of approaches and consequently several distinct measures 
including Michaelis-Menten parameters, redox potentials, redox ratios as well as protein and 
transcript levels have been used to describe the thioredoxin system in vitro and in vivo 
(Figure 1.4). The most commonly utilized approaches and assays used to characterize the 
thioredoxin system components in relation to their roles in disease states are critically 
reviewed below. 
 
1.4.1 Approach 1: Enzyme assays 
Several spectrophoto- and spectrofluorometric methods involving the use of insulin, 
DTNB or FiTC-insulin as a substrate have been developed for the quantification of changes 
in thioredoxin and/or thioredoxin reductase activity which are considered valuable indicators 
in a number of clinical conditions. For example, alterations in activity due to changes in 
cellular redox homeostasis have been reported in cancer (Yoo et al., 2010, Ahrens et al., 


























Figure 1.3 Quantification of thioredoxin (Trx) and/or thioredoxin reductase (TR) in various pathologies. Perturbations of thioredoxin 
and/or thioredoxin reductase have been associated with various pathologies and several quantification methods have been used to determine the 
role played by the system components in each disease. 
Organ: Lungs 
Pathology: Cancer                          
Measure: TR and Trx protein levels 
Method: Immunohistochemistry, Western blot 
Reference: Park et al. (2006)  
 
Pathology: Cancer 
Measure: (1) Trx and TR mRNA levels  
      (2) Trx and TR protein levels 
Method:    (1) RT-PCR  
      (2) Immunohistochemistry, Western  
           blot 
Reference: Soini et al. (2001)  
 
Pathology: Asthma 
Measure: Serum Trx levels 
Method: Sandwich ELISA 
Reference: Yamada et al. (2003)  
 
Organ: Heart 
Pathology: Coronary artery  disease 
Measure:   (1) TR and Trx activities   
      (2) TR and Trx protein levels 
Method:     (1) End-point insulin assay 
     (2) Western blot 
Reference: Wu et al. (2010) 
Organ: Brain 
Pathology: Alzheimer‟s disease 
Measure:   TR activity  
Method:     End-point insulin assay 
Reference: Lovell et al. (2000) 
 
Pathology: Parkinson‟s disease 
Measure:  TR activity 
Method: Mito-TRFS fluorescent probe 
Reference: Liu et al. (2016) 
Organ: Liver 
Pathology: Cancer  
Measure: (1) Trx mRNA levels  
      (2) Trx protein levels 
Method:   (1) Northern blot analysis  
      (2) Immunohistochemistry 
Reference: Kawahara et al. (1996)  
 Organ: Stomach 
 Pathology: Cancer 
 Measure:    Trx protein levels    
 Method:      Immunohistochemistry 















Figure 1.4 Measurement of the thioredoxin system. Perturbations in the thioredoxin 
system have been quantified using several approaches including enzyme assays (A), redox 
states (B), redox potentials (C) as well as transcript and protein levels (D). The thioredoxin 
system components, thioredoxin and/or thioredoxin reductase, are usually measured 
independently (indicated by the red line, A and D respectively) and surprisingly, little or no 
information is available for the quantitative measurement of the complete thioredoxin system 
in vivo. 
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1.4.1.1 Spectrophotometric assays 
  
  1.4.1.1.1 Insulin activity assay 
   Thioredoxins possess insulin disulfide reductase activity and this assay (Holmgren, 
1979a) has been used to characterize the thioredoxins of several species (Alger et al., 2002, 
Jeon and Ishikawa, 2002, Akif et al., 2008, Grimaldi et al., 2008, Yang and Ma, 2010). The 
assay involves the reduction of insulin by thioredoxin which can be monitored 
turbidimetrically by following the aggregation of the free β-chain (Holmgren, 1979b) or by 
coupling the reaction to NADPH oxidation (Holmgren, 1979a, Arnér and Holmgren, 2000a) 
(Figure 1.5). Although commonly used, a key limitation with this assay for biological 
samples such as tissue extracts is that NADPH-metabolizing enzymes can interfere with the 
assay resulting in a high background (Arnér and Holmgren, 2000a). Further, because the Trx 
system is coupled, it may not be immediately apparent if an increase in reported activity is 
caused by increases in Trx and/or thioredoxin reductase. 
 
 
Figure 1.5 Thioredoxin mediated insulin reduction assay. This assay involves the 
reduction of insulin by thioredoxin which can be monitored either by following the 
aggregation of the free β-chain at 650 nm (A) or by coupling the reaction to NADPH and 
monitoring the oxidation of NADPH at 340 nm (B).  
 
1.4.1.1.2 End-point insulin activity assay 
     Due to the small amounts of thioredoxin and/or thioredoxin reductase present in 
complex biological samples, a modified version of the insulin assay was subsequently 
developed in which the thioredoxin system reduces the disulfide bonds of insulin and the 
reaction is stopped by guanidine hydrochloride (Arnér and Holmgren, 2000a). The 
reduced thiol groups of insulin then react with DTNB which upon reduction to 5-thio-2-
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nitrobenzoic acid (TNB) produces a yellow color and has an absorption maximum at 412 
nm which can be monitored spectrophotometrically.  
 
1.4.1.1.3 DTNB assay 
         The DTNB calorimetric assay has also been used to determine the thioredoxin 
reductase activity in mammalian cells and tissues. However, the key limitation with this assay 
is that it is not ideal for cell lysates as these fractions contain other NADPH oxidoreductases 
including lipoamide dehydrogenase and glutathione reductase that are also capable of 
reducing DTNB (Brigelius et al., 1983, Biewenga et al., 1996). The contribution of the 
activities of these enzymes to the total DTNB reduction may be quantified by using a 
thioredoxin reductase inhibitor such as aurothiomalate or auranofin (Saccoccia et al., 2014) 
which significantly increases the cost of the assay. 
  
1.4.1.1.4 SC-TR assay 
   The SC-TR assay uses selenocystine, a commercially available diselenide-bridged 
amino acid as a substrate that can only be reduced by high molecular weight thioredoxin 
reductase. In this continuous assay, the activity of thioredoxin reductase is determined by 
monitoring NADPH consumption at 340 nm as thioredoxin reductase reduces selenocystine 
(Cunniff et al., 2013). This assay was used to compare thioredoxin reductase activity in 
malignant mesothelioma cells compared to control LP9 mesothelial cells and it was found 
that the malignant mesothelioma cell lines had twice the thioredoxin reductase activity when 
compared to the control cells (Cunniff et al., 2013). 
 
 The SC-TR assay offers several advantages in comparison to the traditional assays used to 
determine thioredoxin reductase activity. First, the assays can be performed using traditional 
spectrophotometry or adapted for use in a 96-well plate format, allowing for the analysis of 
multiple experimental parameters at once. Second, this assay is more versatile than other 
methods using cell lysates as it is compatible with the use of non-ionic detergents that are 
commonly used in buffers to lyse mammalian cells (Holden and Horton, 2009, Ji, 2010). 
Third, the assay is both direct and continuous. Fourth, unlike DTNB, selenocystine is 
specifically reduced by thioredoxin reductase and is not a substrate for other NADPH cellular 
reductases making this assay suitable for complete cell lysates. Finally, as the assay uses a 
direct substrate of thioredoxin reductase, there is no need to supply exogenous thioredoxin, 
insulin and DTNB to the reaction mixture. However, a key limitation of this assay is that it is 
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only applicable to mammalian thioredoxin reductase and cannot be used to measure the low 
molecular weight thioredoxin reductase.   
 
     1.4.1.2 Spectrofluorometric methods 
1.4.1.2.1 Fluorescein isothiocyanate-labeled insulin (FiTC–insulin) assay 
          In an attempt to acquire a more sensitive and reproducible assay for the analysis of 
thioredoxin and thioredoxin reductase activities in clinical samples, the fluorescein 
isothiocyanate-labeled insulin (FiTC–insulin) assay was developed (Montano et al., 2014). 
This modified version of the original insulin assay (Heuck and Wolosiuk, 1997b, Heuck and 
Wolosiuk, 1997a) involved the synthesis of fluorescent derivatives of bovine pancreas insulin 
for a spectrofluorometric assay (Montano et al., 2014). FiTC–insulin emits fluorescence at 
520 nm after excitation at 480 nm (Heuck and Wolosiuk, 1997b, Heuck and Wolosiuk, 
1997a) and the fluorescence increases when the disulfide bonds between the insulin A and B 
chains are reduced. The advantage of this assay compared to the traditional insulin assay is 
that Trx has a higher affinity for FiTC-insulin than insulin. Additionally, due to its high 
sensitivity, this assay only requires small sample amounts for activity measurements making 
it suitable for clinical studies (Montano et al., 2014). However like insulin, FiTC–insulin is 
not a physiological substrate for thioredoxin and thus the relevance of a high or low reductive 
activity in this assay may not be readily apparent. 
 
1.4.1.2.2 Thioredoxin Mito-NAPH off−on fluorescent probe  
              The Mito-NAPH probe was developed to visualize mitochondrial thioredoxin 
activity in cells where a fluorescence off-on change is induced by a thioredoxin-mediated 
disulfide cleavage of the probe which can be measured at 540 nm (Figure 1.6). The main 
advantage of this probe is that Trx activity can be detected at concentrations as low as 50 nM 
which is well below its physiological level and the probe can be directed to the mitochondria 
increasing the specificity of the assay. Although innovative, a limitation with this probe is 
that although it preferentially reacts with Trx, other biological sulfur species such as GSH are 
present at relatively high concentrations and the probe also displays a response towards them 





Figure 1.6 Proposed mechanism for the reaction between thioredoxin and Mito-Naph. A 
fluorescence off-on change is induced by thioredoxin mediated disulfide cleavage of the 
probe, resulting in a subsequent intramolecular cyclization by the released thiolate to give a 
fluorescent product which can be measured at 540 nm. (Reprinted with permission from Lee, M. H., 
Han, J. H., Lee, J.-H., Choi, H. G., Kang, C. & Kim, J. S. 2012. Mitochondrial Thioredoxin-Responding Off–On 
Fluorescent Probe. Journal of the American Chemical Society, 134, 17314-17319. Copyright (2012), American 
Chemical Society.) 
 
1.4.1.2.3 Thioredoxin reductase fluorogenic substrate (TRFS)-green fluorescent probe 
         TRFS-green was designed and synthesized for monitoring mammalian thioredoxin 
reductase activity (Zhang et al., 2014) and has been used to image the thioredoxin reductase 
activity in various types of live cells (Liu et al., 2014, Zhang et al., 2015a, Peng et al., 2015b, 
Peng et al., 2015a). Thioredoxin reductase 2 and its respective substrate thioredoxin 2 are 
known to regulate mitochondrial ROS levels and therefore monitoring the activity of 
thioredoxin reductase 2 is of significance for the etiology of various neurodegenerative 
diseases including Parkinson‟s disease (Lopert et al., 2012, Perier and Vila, 2012, 
Subramaniam and Chesselet, 2013, Hu and Wang, 2016) and Alzheimer‟s disease (Arodin et 
al., 2014) which are associated with mitochondrial dysfunction. 
 
The probe contains a 1,2-dithiolane scaffold with a quenched naphthalimide fluorophore 
and displays a green fluorescence off–on change that is induced by a thioredoxin reductase 
mediated disulfide cleavage. This results in an intramolecular cyclization that liberates the 
masked naphthalimide fluorophore (Figure 1.7). The ability to trigger the fluorescent signal 
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by cellular protein extracts correlated well with the endogenous thioredoxin reductase activity 
in different cells (Zhang et al., 2014). A major advantage of this probe is that it shows high 
selectivity towards thioredoxin reductase over other related enzymes. However a key 
limitation with the TRFS-green probe is that it does not accumulate exclusively in the 
mitochondria and instead appears to be evenly distributed in the cytosol (Liu et al., 2016).  
 
1.4.2 Approaches 2 and 3:  Redox states and redox potentials 
Due to its crucial role in regulating normal cellular behaviour, redox status has been 
recognized as a key parameter of biological research in several pathologies. Most procedures 
to measure the redox states of thioredoxin 1 and 2 consist of three main parts: derivatization, 






Figure 1.7 Proposed mechanism of the activation of the TRFS-green probe by 
thioredoxin reductase and NADPH. TRFS-green contains a five-membered, cyclic 
disulfide scaffold which can be selectively cleaved by thioredoxin reductase in the presence 
of NADPH. Upon reduction, the nucleophilic thiolate subsequently attacks the amide 
carbonyl carbon driven by the formation of a five-membered cyclic carbamate, which 
simultaneously releases the quenched fluorophore naphthalimide to activate the green 
fluorescent signal. (Reprinted with permission from Zhang, L., Duan, D., Liu, Y., Ge, C., Cui, X., Sun, J. & 
Fang, J. 2014. Highly Selective Off–On Fluorescent Probe for Imaging Thioredoxin Reductase in Living Cells. 
Journal of the American Chemical Society, 136, 226-233. Copyright (2014), American Chemical Society.) 
 
1.4.2.1 Derivatization and redox western blot 
     When determining the redox state of a protein, samples have to be quenched to trap the 
prevailing thiol-disulfide status. Two approaches are commonly used; the first entails 
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blocking free thiols with a cell-permeable alkylating agent and the second method involves 
the quenching of thiol-disulfide exchange with an acid. As both methods pose advantages and 
disadvantages, the optimal procedure for quenching the thiol-disulfide state was identified to 
be a combination of the two strategies where samples are first quenched with TCA followed 
by alkylation of thiols (Hansen and Winther, 2009). This method allows for the separation of 
the reduced and the oxidized forms of proteins based on their molecular masses using SDS-
PAGE or charge using native or urea PAGE. This procedure is generally used in conjunction 
with western blotting to probe the redox state within cells.  
 
The redox western analysis of thioredoxin, currently the gold standard, provides a 
convenient tool to estimate the redox state of different compartments and improve the 
understanding of redox signalling (reviewed in Go and Jones (2001)). Labelling with thiol 
reagents containing biotin allows selection and/or detection with streptavidin and can 
enhance assay flexibility. However, the major drawback of this approach is that it can be 
difficult to calibrate because of multiple thiols in proteins, non-linear responses and epitope 
changes with thiol oxidation or alkylation (Go and Jones, 2013). Also, the derivatization 
procedure involves tissue destruction and the lysis of cells which may compromise recovery. 
Further, it is difficult to measure redox ratios in different organelles other than by 
cumbersome fractionation of sub-cellular structures. In principle, genetically encoded redox 
probes (Ren and Ai, 2013) could overcome many of these limitations but to the best of our 
knowledge probes specific for Trx are yet to be synthesised. 
 
1.4.2.2 Diagonal SDS-PAGE/2D redox SDS-PAGE 
     Diagonal SDS-PAGE, originally used to analyse intermolecular disulfide bonds 
artificially generated between ribosomal proteins in E. coli (Sommer and Traut, 1974), is a 
proteomic method that allows for a global analysis of the redox state of cellular proteins. This 
method does not require protein purification and can therefore be used in a high-throughput 
manner using cell lysates (Xia et al., 2007). The first step in determining the in vivo 
thiol/disulfide state of proteins involves the rapid blocking of all free thiol groups to prevent 
unwanted thiol-disulfide exchange reactions. This is achieved by addition of a membrane 
permeable thiol trapping reagent either to the intact cells shortly before lysis or to the protein 
extract immediately after cell lysis (Zander et al., 1998). The alkylated protein extract is then 
separated by SDS-PAGE in the first dimension under non-reducing conditions. Upon 
completion of the run, the entire lane is excised, reduced and is applied horizontally to 
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another gel. Following electrophoresis and after staining the gel, three groups of proteins can 
be distinguished. Proteins without disulfide bonds are recovered on the diagonal line because 
their migration behaviour is identical in both dimensions, while proteins with intra- and 
intermolecular disulfides migrate above and below the diagonal line respectively (Cumming 
et al., 2004, Leichert and Jakob, 2004). This method in combination with mass spectrometry 
was used to identify several known disulfide bonded cytoplasmic proteins such as 
peroxiredoxins, thioredoxin reductase, nucleoside-diphosphate kinase and ribonucleotide-
diphosphate reductase that undergo disulfide bond formation upon exposure of cells to 
oxidative stress. Unexpectedly, a significant number of previously unknown disulfide bonded 
proteins were also found including those involved in molecular chaperoning, translation and 
glycolysis (Cumming et al., 2004).  
 
1.4.2.3 Determining the cellular redox potential using the Nernst equation 
    Redox states are often quantified in terms of the steady-state redox potential (Eh) 
because the rates of oxidation and reduction of individual thiols in cells are difficult to 
measure (Go and Jones, 2013). The most common way to determine the cellular Trx redox 
potential is through the Nernst equation (equation 1.1) which incorporates the relative in vivo 
concentrations of the redox couple determined by redox western blotting (Section 1.4.2.1) 
(Hansen et al., 2006, Jones, 2010, Wouters et al., 2010):  
 




            
           
                                                                       (1.1) 
 
 
where 𝐸˚ represents the standard redox potential, R is the universal gas constant, T is the 
absolute temperature in Kelvin, n is the number of moles of electrons transferred and F is the 
Faraday constant. 
 
The cellular redox potential provides a general overview of the thiol disulfide redox state 
of a cellular redox couple and can change dramatically with oxidative influences or 
deficiencies in the cellular redox-balancing systems (Leichert and Jakob, 2004). Several 
advantages have been associated with the use of redox potentials for quantifying the Trx 
system. First, the redox potential follows from studies looking at the redox regulation of 
proteins in vitro, and in some instances a precise relationship could be observed between 
changes in the redox potential of a given redox couple and the in vivo activity of a protein. 
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Second, changes observed in the cellular redox potential have indeed been correlated to 
physiological changes within some cells and tissues (Pillay et al., 2013).  
 
1.4.3 Approach 4:  Transcript and protein levels 
The presence of elevated concentrations of thioredoxin and/or thioredoxin reductase in 
biological fluids and tissues can be useful as a biomarker of oxidative stress in disease states 
(Quiñonez-Flores et al., 2016). Thioredoxin and/or thioredoxin reductase have been shown to 
be over-expressed in many cancers and cancer cell lines (Miyazaki et al., 1998, Arner and 
Holmgren, 2006, Yoo et al., 2007, Hedström et al., 2009) as well as asthma (Yamada et al., 
2003) and neurodegenerative diseases such as Alzheimer‟s disease (Arodin et al., 2014). The 
most common methods used to derive the transcript and/or protein expression levels of the 
thioredoxin system components are discussed below. 
 
1.4.3.1 Reverse transcription polymerase chain reaction (RT-PCR) 
      Reverse transcription polymerase chain reaction (RT-PCR) is commonly used to 
assess gene transcription in cells or tissues. Using this method, patients with non-small cell 
primary lung tumors showed significantly increased levels of thioredoxin mRNA compared 
to the thioredoxin mRNA levels in paired normal lung tissue (Gasdaska et al., 1994) and half 
of human primary colorectal carcinomas examined had increased thioredoxin mRNA 
compared to adjacent normal colonic mucosa from the same subject (Berggren et al., 1996).  
 
RT-PCR has many advantages including high specificity, sensitivity and speed. However, 
the main limitation with this method is that a gene‟s transcript level does not necessarily 
predict its protein level as there is considerable discrepancy between mRNA and protein 
expression, both at steady state expression levels and in response to perturbations (Pascal et 
al., 2008). Quantifying the relationship between protein and mRNA levels can be 
problematic, and previous efforts to find correlations have found variable success. For 
example, Stark et al. (2006) compared the mRNA and protein expression of the p53 gene in 
breast cancer brain metastases versus primary tumors and found that the mRNA level of p53 
was significantly lower in brain metastases but the comparison of the protein levels was 
insignificant. Therefore findings of mRNA expression need to be validated by protein and 




1.4.3.2 Northern blot 
    The northern blot technique is a classical way of analyzing the presence of a specific 
RNA sequence in a sample and has been used to identify differences in the genetic expression 
patterns between healthy and diseased tissues (Josefsen and Nielsen, 2011). Although this 
method is relatively inexpensive, simple to perform and still currently in use (see for example 
Brown et al. (2013), Ikeh et al. (2016)), it has a lower sensitivity when compared to RT-PCR 
and requires a large amount of target RNA sample.  
 
1.4.3.3 Enzyme-linked immunosorbent assay (ELISA) 
  The enzyme-linked immunosorbent assay (ELISA) is the most commonly used method 
to determine the thioredoxin system component levels in human plasma and serum (Miyazaki 
et al., 1998, Park et al., 2014, Wu et al., 2014, Li et al., 2015, Zhang et al., 2015a). The 
clinical significance of serum thioredoxin levels was assessed in acute ischemic stroke (AIS) 
patients using solid-phase sandwich enzyme-linked immunosorbent assay (ELISA) in which 
two highly specific antibodies to the human thioredoxin protein were utilized. Using this 
method, it was found that the serum thioredoxin levels were significantly increased in first-
ever stroke patients compared with those in normal controls and it was concluded that the 
serum thioredoxin levels might be used as an independent diagnostic marker of AIS (Wu et 
al., 2014). This method was also used to measure the serum levels of thioredoxin in patients 
diagnosed with hepatocellular carcinoma (Li et al., 2015) as well as to assess the clinical 
significance of serum thioredoxin levels in children with autism spectrum disorders (ASD) 
where it was observed that the thioredoxin levels were significantly higher in children with 
ASD when compared to typically developing children (Zhang et al., 2015b).  
 
The key advantage of this assay is that it provides a convenient method for the analysis of 
a large number of samples within a single run and requires significantly less sample volume 
compared to other techniques such as northern blotting (Frijhoff et al., 2015). However, an 
important limitation is that human serum samples also contain immunoglobulins that affect 
the results of immunoassays by binding to reagent antibodies used in the assay leading to 
false positive signals (Zhang et al., 2009). In addition, quantifying protein levels yields no 
insights into the redox state of the protein. Finally, elevated thioredoxin levels have been 
associated with multiple conditions and therefore increased serum levels of this protein may 




1.4.3.4 Mass spectrometry 
    Mass spectrometric peptide mapping used in conjunction with protein database 
searching is becoming a popular choice for the rapid identification of proteins. A typical 
protein identification experiment involves the separation of proteins of interest by one-
dimensional or two dimensional polyacrylamide gel electrophoresis. The bands containing 
the proteins of interest are then excised and are in-gel digested by a protease such as trypsin. 
The resulting proteolytic peptides are analyzed by matrix-assisted laser desorption/ionization 
(MALDI) imaging mass spectrometry to yield a peptide mass map. Identification of proteins 
is achieved by searching for the best match between the experimentally determined masses in 
the peptide map and those calculated by theoretical cleavage of each of the proteins in an 
appropriate sequence database (Aebersold, 2003). Extensive application of mass 
spectrometric methods to neurodegenerative diseases such as Alzheimer‟s disease and 
Parkinson‟s disease, as well as other human diseases and animal models, have established the 
value of these approaches in improving our mechanistic understanding of redox biology and 
human disease (Butterfield et al., 2006).  
 
1.4.3.4 Redox proteomics 
  In contrast to the measurement of individual biomarkers, proteomic analysis aims to 
identify a panel of complementary biomarkers that are either up- or downregulated with 
altered post-translational modifications which differ in pathological and normal states and 
can therefore give extensive information regarding a disease. This approach has an advantage 
over mRNA expression analysis as it directly focuses on the actual biological effector 
molecules and provides more accurate functional information about biological systems (Shiio 
and Aebersold, 2006). 
  
Redox proteomics is a rapidly advancing area of proteomics focused on identifying and 
quantifying redox-based changes within the proteome during redox signaling and under 
oxidative stress conditions (Rinalducci et al., 2008). It also aims to broaden the information 
available concerning potential biomarkers for disease diagnosis and provide insights into 
perturbed redox metabolic networks and potential targets for modulation of disease 
progression by means of drug therapy. In addition to the methods previously mentioned 
(Section 1.3), a number of other redox proteomics methods have been developed. An 
example of a redox proteomics approach involves the use of isotope-coded affinity tags 
(ICATs) with three functional moieties: a cysteine reactive moiety, a linker containing either 
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a heavy (contains eight deuteriums) or light (contains eight hydrogens) isotope resulting in a 
mass difference between the two, and a biotin affinity tag used to isolate ICAT-labeled 
peptides. Using this technique, the cysteine side chains in complex mixtures of proteins from 
two different states of a cell population such as normal and disease conditions are labeled 
with isotopically light and heavy ICAT reagents. The two mixtures are then combined and 
after tryptic digestion to form peptides, the labelled peptides are affinity-purified using an 
avidin column and are then analyzed by mass spectrometry. The quantitative information 
based on the relative abundance of the light and heavy isotopes is obtained and the 
identification of proteins is determined from the peptide molecular mass and amino acid 
sequence (Gygi et al., 1999, Aebersold et al., 2007).  
 
 The ICAT technique has significantly expanded the range of proteins that can be analyzed 
including low-abundance, hydrophobic or highly charged proteins, and also allows accurate 
quantification and concurrent sequence identification of individual proteins in complex 
mixtures (Shiio and Aebersold, 2006). While the ICAT approach provides a widely 
applicable means to compare quantitatively global protein expression in cells and tissues 
(Gygi et al., 1999),  it displays insufficient proteome coverage and it is estimated that only 
10-20% of the whole cell proteome can be analyzed in a single ICAT experiment (Shiio and 
Aebersold, 2006). 
 
1.5 Limitations with the current quantification methods for the 
thioredoxin system: could a systems biology approach be the solution? 
 
In addition to the methodological limitations within each approach outlined above, several 
limitations have been identified with the actual measures chosen to characterize the 
thioredoxin system. For example, the enzyme assay approach is limited as a number of 
inconsistencies exist in the description of thioredoxin as an enzyme. In contrast to the 
catalytic cycles of conventional enzymes, thioredoxins become oxidized and therefore 
inactive after reacting with their substrates. A separate enzyme-catalysed reaction is required 
to return thioredoxin to its active form (Figure 1.1-1.2) and a varying turnover number has 
been reported for the reduction of insulin by thioredoxin suggesting that Michaelis-Menten 
parameters should not be used to quantify thioredoxin activity (Pillay et al., 2009). Further, 
monitoring changes in thioredoxin reductase activity alone, may also be an inadequate 
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measure of the thioredoxin system which is comprised of several subsystems that can affect 
each other through the Trx redox cycle (Pillay et al., 2011).  
 
On the other hand, data from cultured cells and tissues had suggested that redoxins should 
be characterized as redox couples (Trotter and Grant, 2003, Watson et al., 2004), and 
quantified with redox ratios and potentials and not by enzyme kinetic parameters and activity 
measurements which has further complicated the quantification of the Trx system. However, 
theoretical studies have also questioned the validity and usefulness of cellular redox 
potentials and have suggested that kinetic rather than thermodynamic regulation may be a 
more important consideration because the Nernst equation only provides a measure of the 
thermodynamic potential. The equation gives no indication of whether reactions actually 
occur or the rates of these reactions within a given system and thus while the Nernst equation 
may have some correlative value to physiological changes, its predictive capacity has been 
limited (Flohé, 2010, Flohé, 2013, Pillay et al., 2013). 
 
Although measurement of protein levels has been informative, this data is inherently 
incomplete as elevations in these levels can be ambiguous as they may reflect either an 
increase in protein production or a decrease in turnover. As described above, a major 
limitation with the analysis of transcript levels alone is that these levels may not be able to 
predict the corresponding protein levels. The isolated assessment of protein levels is also 
inadequate as it provides no information regarding protein activity and therefore it might be 
best to concurrently measure the catalytic activity of the protein. 
 
Given the multiple approaches taken to quantify the Trx system and the limitations 
associated with each one, it is unclear which measure provides the most accurate description 
of the role played by the system in pathological states (Figure 1.3). Also, efforts aimed at 
alleviating pathologies associated with Trx system perturbations may have been limited as 
these diseases involve a large variety and number of elements that interact via complex 
networks and nonlinear interactions (Wang, 2010). Therefore, analysis and quantification of 
system constituents in isolation or knocking out a single target molecule in a biochemical 
pathway may be insufficient for analysing the role of the Trx system in a pathology 
(Hornberg et al., 2006, Wang, 2010). It is increasingly believed that a systems approach, 
rather than the current gene-centric view could solve these problems (Wang, 2010, Loscalzo 
and Barabasi, 2011) because developing an understanding of the complex systems involved 
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in various pathologies might make it possible to develop more efficient therapeutic strategies 
which could lead to significant advances in the treatment of disease (Wang, 2010). 
Consequently utilizing a system measure such as flux may provide better insight into the 
steady state behaviour of the thioredoxin network as a whole. However as measuring flux in 
vivo is experimentally challenging, computational modeling has often been used (Sauer, 
2006). 
 
Computational methods allow for the generation of in silico models of cells, tissues and 
organs with the aim of simulating the steady state and dynamic properties of a system. Using 
this approach, several computational models of the thioredoxin system have been developed 
to elucidate the behavior of the system (Adimora et al., 2010, Pillay et al., 2011, Benfeitas et 
al., 2014, Tomalin et al., 2016). An advantage of this approach is that the flux can be 
estimated through computational model-based interpretation of experimental data (Sauer, 
2006). However a limitation with this inference approach is that it relies on data fitting 
experiments and therefore the development of accurate models. 
 
In this regard, a major hurdle faced during thioredoxin computational modeling studies 
was whether to describe thioredoxin as an enzyme or as a redox couple as conflicting 
measures of thioredoxin activity have been reported in the biochemical literature (detailed in 
Pillay et al. (2009), Pillay et al. (2013)). Specifically, if thioredoxin was modeled as an 
enzyme, then it should appear in the rate vector (v) of the kinetic model equation (equation 
(1.2), but if it was modeled as a redox couple, then it should appear in the stoichiometric 
matrix (N) of that equation (Terzer et al., 2009, Pillay et al., 2013): 
 
     
   
  
=                          (1.2) 
where si refers to the species within the kinetic model. 
 
Using computational modeling, it was proposed that thioredoxin should be modeled as a 
redox couple, that mass action kinetics were sufficient to describe thioredoxin activity and 
that the Michaelis-Menten parameters assigned to thioredoxin were unreliable. It was also 
proposed that the in vitro enzymatic properties attributed to thioredoxin resulted from the 
saturation of the thioredoxin redox cycle and not thioredoxin itself (Pillay et al., 2009). A 
number of computational models have subsequently been built using this approach (Adimora 
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et al., 2010, Pillay et al., 2011, Benfeitas et al., 2014, Tomalin et al., 2016). However, prior 
and subsequent kinetic fitting studies from other groups support the description of 
thioredoxin and indeed other redoxins as enzymes (Holmgren, 1979a, Juttner et al., 2000, 
Bao et al., 2009, Maeda et al., 2010, Obiero et al., 2010, Chen et al., 2014) which has 
questioned the applicability of the computational modeling approach.  
 
1.6 Aims of study 
 
Given the ambiguous description of thioredoxin activity, the first aim of this research was to 
confirm the kinetic mechanism of the thioredoxin system in order to accurately model this 
network for system biology applications. This aim involved computational and molecular 
methods including the cloning, expression and purification of the thioredoxin system from 
Saccharomyces cerevisiae and the generation of substrate saturation curves using insulin as a 
model substrate. As model inference is currently the only available way to obtain a flux through 
the system, finding an independent and experimentally tractable surrogate measure for this flux 
would represent a significant advance and was therefore the second aim of this study. To achieve 
this objective, simulations of thioredoxin system computational models as well as in vitro assays 
were performed to determine which of the measures of the thioredoxin system was a 











The initial step in the isolation of a protein is to choose a method of measuring the 
presence of the protein and of distinguishing it from all other proteins that might be present in 
the same material. This is achieved by an activity assay which measures the unique activity of 
the protein and allows various materials to be analyzed so that the one containing the largest 
amount of the desired protein, can be used as the starting material (Dennison, 2003). Usually, 
the more specific the assay, the more effective the purification is (Berg et al., 2002).  
 
Once a source material has been selected, the protein must be extracted in a soluble form 
suitable for manipulation. The object of extraction is to get the target protein out of the 
cellular material where it is located and into solution so that it can be manipulated. This can 
be achieved by homogenisation, which disrupts the tissues and breaks open the cells to 
release their contents. The extract can then be clarified by either filtration or centrifugation. 
The crude extracts containing the desired protein are thereafter purified on the basis of 
characteristics such as solubility, size, charge and specific binding affinity (Dennison, 2003).  
 
The original methods employed in the purification of Trx and thioredoxin reductase were 
tedious and time consuming (Williams et al., 1967) and were replaced with cloning 
technologies which were simpler and faster (Gasdaska et al., 1995, Miranda-Vizuete et al., 
1997, Serrato et al., 2002, Kim et al., 2005). The sections below describe the materials and 
methods used to isolate the Trx system. The methods section is divided into separate sub-
sections with descriptions because of the range of techniques covered. All the results are 




TEMED, ammonium persulfate, Coomassie brilliant blue R-250 powder, dithiothreitol 
(DTT), bovine pancreas insulin, 5, 5'-dithiobis(2-nitrobenzoic acid) (DTNB), β-nicotinamide 
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adenine dinucleotide phosphate (NADPH), bovine serum albumin (BSA), isopropyl β-D-1-
thiogalactopyranoside (IPTG), kanamycin, ampicillin and 4-(2-aminoethyl)benzenesulfonyl 
fluoride hydrochloride (AEBSF) were obtained from Sigma (Capital Labs, South Africa) 
while RNase A was obtained from Roche (South Africa). A Rapid DNA Ligation Kit, the 
Thermoscientific Gel Extraction Kit, the InsTAclone
TM
 PCR cloning kit, TransformAid
TM
 
Bacterial Transformation Kit and Taq
TM
 DNA polymerase were obtained from Inqaba 
Biotech (Johannesburg, South Africa) while the QIAquick
TM
 Gel Extraction Kit, agarose for 
gel electrophoresis and Ni-NTA agarose were obtained from Whitehead Scientific (Pty) Ltd 
(Cape Town, South Africa). The New England Biolabs HindIII, NdeI and BamHI restriction 
enzymes were obtained from The Scientific Group (Midrand, South Africa) and Acrylamide-
Bis ready to use solution (37.5:1) and Polyethylene glycol (PEG) 20,000 were obtained from 
Merck (South Africa). All other common chemicals were obtained from Saarchem (Merck, 
South Africa) and were of the highest purity available. pET28a was generously donated by 
Professor Dean Goldring (Biochemistry, UKZN) and the thioredoxin reductase  clones 
(pMPTRRA, B, C and D) were generously supplied by Miss M.M Photolo (Genetics, UKZN) 
.  
 
2.3 Preparation of common reagents 
 
The preparation of all common reagents has been described in the text below whilst the 
preparation of specialized reagents will be described later in the chapter. 
 
2.3.1 DTT 
A fresh stock solution of DTT (1 M) was prepared at the time of use by dissolving DTT 
powder (0.154 g) in ddH2O (1 ml). 200 µl of this stock solution was made up to 2 ml with 
ddH2O and the resulting DTT solution (final concentration 100 mM) was used in the Trx 
activity assay. 
 
2.3.2 Bovine pancreas insulin 
A 1.6 mM stock solution of insulin was prepared by suspending insulin (50 mg) in  0.5 ml 
100 mM potassium phosphate buffer (pH 6.5). The pH was adjusted to 2-3 with 1 M HCl to 
dissolve the protein completely and was thereafter titrated back to the original pH of the 
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buffer (pH 6.5) with NaOH (1 M). Finally, the volume was adjusted to 5 ml with ddH2O. The 
clear insulin solution was stored at – 20°C.  
 
2.3.3 DTNB 
A stock solution of DTNB (62.1 mM, final concentration) was freshly prepared by 
dissolving DTNB powder (0.025 g) in 99% ethanol (1 ml). The resulting solution was stored 
in the dark as DTNB is light sensitive.  
 
2.3.4 NADPH 
Stock vials were prepared by keeping 10 mg portions of NADPH (dry) in separate small 
microcentrifuge tubes at -20°C. At the time of use, a single tube was dissolved in ddH2O 
(250 µl) and the final concentration was spectrophotometrically confirmed at 340 nm using 






2.3.5 IPTG stock solution 
A stock solution (100 mM) was prepared by dissolving IPTG powder (0.238 g) in dH2O 
and the volume was made up to 10 ml. This suspension was filter sterilized using a 0.2 μm 
filter (Merck, South Africa). 
 
2.3.6 Kanamycin stock solution 
A stock solution (30 mg/ml) was prepared by dissolving kanamycin sulphate (0.3 g) in 
dH2O. The volume was made up to 10 ml. This suspension was filter sterilized using a 
0.2 μm filter (Merck, South Africa) and stored in 1 ml aliquots at -20°C. 
 
2.3.7 Ampicillin stock solution 
A stock solution (25 mg/ml) was prepared by dissolving ampicillin sodium salt (0.25 g) in 
dH2O. The volume was made up to 10 ml. This suspension was filter sterilized using a 




2.3.8 Bacterial growth media 
 
2.3.8.1 Luria Bertani (LB) broth 
Tryptone (1% (w/v)), yeast extract (0.5% (w/v)) and NaCl (0.5% (w/v)) were dissolved in 
dH2O and the solution was made up to the desired volume. The solution was autoclaved and 
stored at room temperature. When necessary, the appropriate antibiotic, either kanamycin 
(30 μg/ml, final concentration) or ampicillin (50 μg/ml, final concentration) was added.  
 
2.3.8.2 Luria Bertani (LB) agar 
Tryptone (1% (w/v)), yeast extract (0.5% (w/v)), NaCl (0.5% (w/v)) and bacteriological 
agar (1.5% (w/v)) were dissolved in dH2O and the solution was made up to the desired 
volume. The solution was autoclaved and upon cooling, media was poured into petri dishes. 
When necessary, the appropriate antibiotic, either kanamycin (30 μg/ml, final concentration) 
or ampicillin (50 μg/ml, final concentration) was added. The plates were stored at 4°C. 
 
2.3.8.3 Yeast Peptone Dextrose (YPD)  
Yeast extract (1% (w/v)), peptone (2% (w/v)) and dextrose (2% (w/v)) were dissolved in 
dH2O and the solution was made up to the desired volume. The solution was autoclaved and 
stored at room temperature.  
 
2.3.8.4 SOC media 
Yeast extract (0.5% (w/v)), tryptone (2% (w/v)), NaCl (10 mM), KCl (2.5 mM) and 
MgCl2 (10 mM) were dissolved in dH2O and the solution was made up to the desired volume. 
The solution was autoclaved and once cooled, glucose (20 mM, final concentration) was 
added. The glucose solution (1 M) was sterilized by passing it through a 0.2 μm filter. The 
SOC media was then stored at 4°C. 
 
2.3.8.5 2xYT media 
Tryptone (1.6% (w/v)), yeast extract (1% (w/v)) and NaCl (0.5% (w/v)) were dissolved in 
dH2O. The pH was adjusted to 7.0 with NaOH and the volume was made up with dH2O. The 




2.4 The yeast thioredoxin activity assay 
 
There are a number of assays that have been developed to test the activity of Trx 
(Chapter 1). However, many of these assays require thioredoxin reductase (Luthman and 
Holmgren, 1982, Jeon and Ishikawa, 2002, Grimaldi et al., 2008) and commercial Trx assay 
kits are relatively expensive. Current assays for Trx are therefore constrained by the cost and 
availability of pure enzyme and it was important to develop a novel Trx activity assay that 
was inexpensive and allowed for the rapid identification of the target molecules in crude 
extracts.  
 
Holmgren (1979b) showed that the rate of the reduction of insulin disulfides by DTT was 
low but the addition of E. coli Trx to the reaction mixture increased the rate of reduction 
significantly. These findings could be used as the basis for an activity assay for Trx and as 
pure thioredoxin reductase was no longer needed, the cost of the assay was greatly reduced. 
However, a potential problem with this assay was that it took over 20 min before a result was 
obtained (Holmgren, 1979b).  
 
2.4.1 Methods to determine Trx activity 
 
To determine the activity of Trx, a number of assay conditions were tested based on data 
in Holmgren (1979b) which included variations in insulin (0.01 mM and 0.13 mM) and DTT 
(0.33 mM and 1 mM) concentrations as well as the pH of the potassium phosphate buffer 
(pH 6.5 and 7.0). Each reaction mixture contained 2 mM EDTA and proceeded at 25°C 
(Holmgren, 1979b). A modified version of the original assay (Holmgren, 1979b) involving 
the incubation of all components for 20 min at 25°C prior to absorbance readings being 
taken, was also attempted (Sigma-Aldrich, 1994). However in this study, a method involving 
the reduction of the Trx by preincubating 0.1 M DTT (10 μl) with the Trx containing crude 
extract for 10 min at 25°C was developed. A master mix containing 84 mM potassium 
phosphate buffer (pH 7.0), EDTA (2.67 mM) and insulin (0.21 mM) was made into a final 
volume of 9 ml. Thereafter the reaction was initiated by addition of the preincubated 
suspension (250 µl) to the master mix (750 µl). The final reaction mixture contained 63 mM 
potassium phosphate buffer (pH 7.0), EDTA (2 mM), insulin (0.01 mM) and DTT (1 mM) in 
a final volume of 1 ml. The change in absorbance at 650 nm was directly monitored using a 
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sample without the addition of the crude extract as the reference cuvette. Absorbance 
measurements were made with a UV-1800 Shimadzu Spectrophotometer. 
 
2.5 The yeast thioredoxin reductase activity assay 
 
The thioredoxin reductase assay involves monitoring either NADPH oxidation or direct 
reduction of a substrate such as 5, 5'-dithiobis(2-nitrobenzoic acid) (DTNB). In the former 
assay, the oxidation of NADPH is monitored spectrophotometrically in a mixture containing 
potassium phosphate, KCl, EDTA and NADPH as well as oxidized Trx and thioredoxin 
reductase,. However, the limitation with this method is that purified Trx is required. Trx, the 
natural substrate of thioredoxin reductase, is very expensive and difficult to obtain so the 
activity of thioredoxin reductase is usually assayed using an alternate substrate. 
 
The alternative assay to measure the activity of thioredoxin reductase is by monitoring the 
change in absorbance at 412 nm occurring as a result of the reduction of DTNB to TNB 
which has proven to be sufficiently  specific (Arnér and Holmgren, 2000a, Štefanková et al., 
2006). It was also shown that the use of univalent cations in this assay significantly increased 
the rate of reduction (Lim and Lim, 1995). It has been proposed that these cations may induce 
a conformational change in E. coli thioredoxin reductase in which its closed conformation is 
converted to an open conformation thereby exposing the active site (Lim and Lim, 1995).  
 
2.5.1 Methods to determine thioredoxin reductase activity 
  
To determine the activity of thioredoxin reductase, a number of assay conditions were tested 
including DTNB (1 mM - 5 mM) and NADPH (0.3 mM - 0.5 mM) concentrations, the pH of 
the potassium phosphate buffer (pH 7.0 and 7.2) (Arnér and Holmgren, 2000a, Štefanková et 
al., 2006) and the effect of including univalent cations (NaCl) within the reaction (Lim and 
Lim, 1995). The final reaction mixture used in this study contained 0.1 M Tris-Cl (pH 8.0), 
0.5 mM DTNB, 0.24 mM NADPH, 0.01% BSA, 0.5 M NaCl and crude extract containing 
TrxR in a final volume of 1 ml.  The reaction was initiated by the addition of the crude 
extract and proceeded at 25°C with the change in absorbance at 412 nm being directly 
monitored using a sample without the crude extract as the reference cuvette. Absorbance 
measurements were made with a UV-1800 Shimadzu Spectrophotometer. 
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2.6 Cloning of Trx 
 
2.6.1 Isolation of genomic DNA from S. cerevisiae 
 Yeast genomic DNA was isolated utilizing the Bust „N Grab method (Harju et al., 2004). 
Briefly, two 1.5 ml samples of a 16 hour yeast culture grown in YPD were pelleted by 
centrifugation (20,000 x g, 5 min, room temperature). The pellet was completely resuspended 
in 200 µl of lysis buffer (2% (v/v) Triton X-100, 1% (w/v) SDS, 100 mM NaCl, 10 mM Tris-
HCl (pH 8.0) and 1 mM EDTA (pH 8.0)) by gentle inversion of the tubes. The tubes were 
then incubated at -75°C until the contents was completely frozen (5 min) and were then 
rapidly transferred to a 95°C water bath (1 min) to allow the contents to thaw. This process 
was repeated three times and thereafter the tubes were vortexed for 30 seconds. Chloroform 
(200 µl) was added to each tube followed by vortexing (2 min). Upon centrifugation 
(20,000 x g, 5 min, room temperature), three distinct layers could be seen and the upper 
aqueous phase was transferred to a clean eppendorf tube containing 400 µl ice-cold 100% 
ethanol. The tubes were gently inverted and incubated for 5 min at -20°C for precipitation of 
the DNA. The precipitated DNA was pelleted by centrifugation (20,000 × g, 5 min, room 
temperature), washed with 70% (v/v) ethanol (0.5 ml), air-dried and re-suspended in 50 µl TE 
buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA (pH 8.0)). These samples were assayed at 
260 nm and 280 nm to determine DNA concentration and purity (Section 2.6.12) and were 
also analyzed by agarose gel electrophoresis (Section 2.6.11). 
 
2.6.2 PCR 
 To amplify the TRX1 gene, PCR was performed using yeast TRX1 specific primers, 5‟-
AGCCATATGGTTACTCAATTCAAAACTGCC-3' and 5'-ACGAAGCTTAAGCATTAGC 
AGCAATGGC-3' (NdeI and HindIII sites are underlined, respectively). These primers were 
designed using Primer3 (http://frodo.wi.mit.edu) and the Trx sequence was obtained from the 
Saccharomyces genome database (SGD) (http://www.yeastgenome.org, Gene ID 850732). 
The primers were designed so that there was an overlap between the start codon and the 
restriction site of NdeI whilst the HindIII restriction site overlapped with the stop codon. This 
design ensured that more of the coding sequence was included in the primer, increasing the 
accuracy of the PCR. The PCR reaction mixture consisted of Taq
™
 DNA polymerase (0.5 U), 
reaction buffer (1X), a dNTP mix (0.2 mM), the forward and reverse primers (250 nM each) 
and DNA (0.01-1 µg) in 25 µl. The following PCR cycling conditions were used: 95°C, 
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3 min (initial denaturation); 95°C, 30 sec; 55°C, 30 sec; 72°C, 30 sec (30 cycles) and a final 
extension at 72°C, 7 min. For all PCR experiments a no template control was included in 
order to check for contamination and the PCR products were analyzed by gel electrophoresis 
(Section 2.6.11). 
 
2.6.3 Mini-prep procedure for purification of plasmid DNA 
 Plasmid DNA was purified using the standard mini-prep procedure (Sambrook et al., 
1989). Two 10 ml samples of an overnight culture grown in LB (containing the appropriate 
antibiotic) were centrifuged (7,250 x g, 5 min, 4°C). The pellet was resuspended in 
200 μl GTE solution (25 mM Tris-Cl (pH 8.0), 10 mM EDTA, 50 mM glucose), 
RNase A (2 μl) was added and the suspension was incubated at room temperature for 5 min 
before being transferred to a sterile eppendorf tube. 400 μl NaOH/SDS solution 
(0.2 M NaOH, 1% (w/v) SDS) was added to lyse the cells and the suspension was mixed by 
gentle finger tapping followed by incubation on ice for 5 min. 3 M potassium acetate solution 
(300 μl) was added and the suspension was incubated on ice for 5 min before being 
centrifuged (12,000 x g, 5 min, room temperature). Isopropanol (600 μl) was added to the 
supernatant (800 μl) and incubated at -20°C for 30 min. The suspension was centrifuged 
(12,000 x g, 5 min, room temperature) and the pellet was washed with ice-cold 70% ethanol 
(500 μl) to remove salt. The pellet was then resuspended in 50 µl TE buffer (10 mM Tris-HCl 
(pH 8.0), 1 mM EDTA (pH 8.0)).  
 
2.6.4 Restriction Digestion 
 Plasmid DNA was routinely restricted with either BamHI or HindIII to linearise the DNA 
for sizing. In these reactions, plasmid DNA (1 µg), restriction enzyme (2 U), buffer (1 X) and 
for a BamHI digest, BSA (0.1 µg/ µl) were incubated at 37°C for 2 hours. For cloning 
experiments, plasmid DNA was restricted with HindIII and NdeI to liberate the TRX1 
fragment. In these reactions, plasmid DNA (37.5 µg), restriction enzyme (2 U each) and 
nuclease free water were all incubated with 1X NEBuffer 2 at 37°C for 4 hours. 
 
2.6.5 Gel purification and Ligation 
 The amplified TRX1 fragment was gel purified using the QIAquick
TM
 Gel Extraction Kit 
and thereafter ligated with the pTZ57R/T vector using the InsTAclone
TM
 PCR cloning kit to 
yield the pTrxA, pTrxB and pTrxC clones. A typical reaction mixture contained the 
pTZ57R/T vector DNA (0.165 µg), purified PCR fragment (at 3: 1 molar excess over vector), 
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Ligation buffer (1 X), T4 DNA Ligase (5U/µl) and nuclease free water. The pTZ57R/T 
vector was transformed into E. coli JM109 cells using a TransformAid
TM
 Bacterial 
Transformation Kit according to the manufacturer‟s instructions. As a positive control for 
competent cell growth, E. coli JM109 competent cells were plated onto a LB agar plate with 
no antibiotic and as a negative control, untransformed cells were plated onto LB plates 
containing ampicillin (50 µg/ml). To purify the recombinant pTZ57R/T DNA, a plasmid 
mini-prep procedure was performed (Section 2.6.3). PCR (Section 2.6.2) using the purified 
recombinant plasmid as a template was done to confirm the presence of the TRX1 insert. A 
restriction digestion using BamHI was also performed to linearise the vector for sizing and 
the vector was digested with HindIII and NdeI to liberate the TRX1 fragment.  
 
2.6.6 Plasmid DNA extraction of pET28a 
 The expression vector, pET28a, was isolated from E. coli BL21 (DE3) cells using a 
plasmid DNA extraction procedure (Section 2.6.3). A260 and A280 readings of the samples 
were taken to determine DNA concentration and purity and these samples were also analyzed 
by agarose gel electrophoresis (Section 2.6.11). 
 
2.6.7 Gel purification and Ligation 
 Restriction digested pET28a (section 2.6.4) and the liberated TRX1 fragment were both gel 
purified using a Fermentas Gel Extraction Kit. The gel-extracted TRX1 fragment and 
restricted pET28a expression vector were subsequently ligated using a Rapid DNA Ligation 
Kit (Fermentas) to form the expression plasmids pLPTrxA, pLPTrxB and pLPTrxC. A 
typical ligation mixture contained vector DNA (10 – 100 ng), insert DNA (at 3: 1 molar 
excess over vector), 1X Rapid Ligation Buffer, T4 DNA Ligase (5U/µl) and nuclease free 
water. The mixture was incubated at 4°C overnight and was then used for transformation. 
 
2.6.8 Preparation of competent cells using the calcium chloride method 
 A calcium chloride (CaCl2) method (Sabel'nikov et al., 1977) was used to make E. coli 
BL21 (DE3) competent cells. E. coli BL21 (DE3) cells were cultured in 2xYT medium until 
an OD600 (0.3-0.4) was reached. Two 10 ml samples were transferred to ice-cold sterile tubes, 
incubated on ice for 10 min and thereafter centrifuged (4,500 x g, 10 min, 4°C). The pellet 
was resuspended in ice-cold 0.1 M calcium chloride (10 ml). The suspension was centrifuged 
(4,500 x g, 10 min, 4°C) and the pellet was resuspended in ice-cold 0.1 M calcium 
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chloride (2 ml) followed by a 30 min incubation on ice. These competent cells were then used 
for transformation.  
 
2.6.9 Transformation of E. coli BL21 (DE3) with pET28a 
 The ligation mix (1 µl) was added to the competent cells (20 µl) and incubated on ice 
(30 min). This mixture was then heat shocked (42°C, 90 sec) and immediately placed on ice 
(2 min). Pre-warmed (37°C) SOC media (80 µl) was added to the cells and the cells were 
incubated for 1 hour at 37°C in a shaking water bath. The transformation mix (50 µl) was 
plated onto LB agar plates containing kanamycin (30 µg/ml) and incubated at 37°C 
overnight. As a control for competent cell growth, E. coli BL21 (DE3) competent cells were 
plated onto a LB agar plate (no antibiotic) whilst in the control for antibiotic activity, 
untransformed E. coli BL21 (DE3) competent cells were plated onto the selective medium. 
As a control for the competency, E. coli BL21 (DE3) cells were transformed with the pET28a 
expression vector (70 ng). To confirm the identity of the clones obtained, a colony PCR using 
the reaction conditions described above (Section 2.6.2) was done and the plasmid DNA was 
purified and restricted with HindIII to linearize the vector for sizing. 
 
2.6.10 Colony PCR 
 Sections of single colonies from the transformation plate were selected, dissolved in 
autoclaved distilled water (25 µl) and incubated in a water bath (2 min, 100°C). This mixture 
was centrifuged (13,000× g, 2 min, room temperature) and 2 µl of the supernatant was used 
to perform a PCR using the conditions described above (Section 2.6.2). 
 
2.6.11 Agarose gel electrophoresis 
Analysis of isolated genomic and plasmid DNA was carried out on 1 % (w/v) agarose gels 
while restriction digestion and PCR products were carried out on 2 % (w/v) agarose gels. 
Gels were prepared by dissolving agarose in 50 ml 1 x TAE buffer (40 mM Tris, 
20 mM acetic acid, 1 mM EDTA, pH 8.0) by gentle heating over a bunsen burner. Once 
cooled, 2 μl of ethidium bromide (10 mg/ml) was added, the gel was poured into the casting 
tray and allowed to polymerize (30 min). Gels were run at 90 V until the bromophenol blue in 
the loading buffer (30% (v/v) glycerol, 0.25% (m/v) bromophenol blue) had migrated 
approximately ¾ down the gel and thereafter photographed under ultraviolet light. A standard 
curve, relating log molecular weight to the distance travelled by each fragment (mm) was 
constructed and used to determine the size of the bands of interest, through extrapolation. 
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2.6.12 DNA quantification  
The NanoDrop™ 2000 UV-Vis Spectrophotometer (Thermo Scientific, South Africa) was 
used to determine the purity and concentration of the DNA. The concentration was measured 
in ng/µl. 
 
2.6.13 Induction and optimization of expression 
 Protein expression of the pET28a clones (pLPTrxA, B, C) was induced by culturing 
selected clones in LB media (30 µg/ml of kanamycin) until an OD600 (0.3-0.4) was reached. 
Isopropyl β-D-1-thiogalactopyranoside (IPTG, final concentration 0.5 mM) was added to 
cultures which were incubated at 37°C in a shaking waterbath. Following IPTG addition, 
samples were taken every 30 min and an OD600 was measured. To optimize expression, 
samples were also taken at 2, 4, 6, 17 and 19 hours and an OD600 was measured. All samples 
were centrifuged (12,000 × g, 10 min, 4°C) and re-suspended in water to a final OD600 of 10. 
This step ensured that approximately equal concentrations of protein were compared over the 
course of the induction experiment. An equal volume of 2 × sample buffer (125mM Tris-
HCl, 4% (m/v) SDS, 20% (v/v) glycerol, 10% (v/v) mercaptoethanol, 
0.01% (m/v) bromophenol blue, pH 6.8) was added to 20 µl of the re-suspended samples and 
the samples were analyzed by SDS-PAGE (Section 2.3). For the optimization experiments, 
cells were also sonicated, centrifuged (15,000 × g, 20 min, 4°C) and thereafter the 
supernatant was subjected to the insulin activity assay (Section 2.4.1). The activity of each 
sample was calculated and this was used to determine the optimal expression time for 
purification.  
 
2.6.14 Tris-Tricine sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) 
Tricine SDS-PAGE is commonly used to resolve smaller proteins in the mass range 1-
100 kDa which are sometimes poorly resolved by the conventional Laemmli SDS-PAGE 
system (Schägger, 2006). In this system, tricine is used as the trailing ion in the stacking 
phase and allows a resolution of small proteins at lower acrylamide concentrations than in 
glycine SDS-PAGE systems (Schägger and von Jagow, 1987). Protein samples, prepared in 
either reducing or non-reducing treatment buffer (125mM Tris-HCl, 4% (m/v) SDS, 
20% (v/v) glycerol, 0.01% (m/v) bromophenol blue, 10% (v/v) 2- mercaptoethanol (only 
present in reducing buffer), pH 6.8) and boiled for 5 minutes prior to loading, were visualised 
on a 15% Tris-Tricine gels (Table ) which comprised of acrylamide: bis (37:5:1) ready to use 
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solution, Gel Buffer (3 M Tris-HCl, 0.3% (m/v) SDS, pH 8.45) and dH2O. Polymerisation 
was initiated with TEMED and freshly prepared ammonium persulfate (10% (w/v)). The gels 
were run at 42 mA with unlimited voltage using cathode (0.1 M Tris-HCl, 0.1 M Tricine, 
0.1% (m/v) SDS, pH 8.25) and anode buffer (0.2 M Tris-HCl, pH 8.9) and were stopped 
when the tracking dye reached the bottom of the gel. Upon completion of electrophoresis, 
gels were soaked in Coomassie blue stain (0.125% (m/v) Coomassie brilliant blue R-250, 
50% (v/v) methanol and 10% (v/v) acetic acid) overnight at room temperature with gentle 
agitation. The stain was then removed and the gels were soaked in destain I solution 
(50% (v/v) methanol, 10% (v/v) acetic acid) on a shaker until background staining was 
reduced. Gels were then transferred to destain II (5% (v/v) methanol, 7% (v/v) acetic acid) 
and thereafter photographed under white light. 
 
Table 2.1 Preparation of the resolving and stacking gels for Tris-tricine SDS-PAGE 
Reagents                            Resolving gel (ml)  Stacking gel (ml) 
Monomer          8.0      0.67 
Gel Buffer         4.0      1.25 
dH2O           3.71      3.00 
Ammonium persulfate     0.240      0.050 
TEMED          0.016      0.010 
 
2.7 Cloning of thioredoxin reductase 
 
2.7.1 Colony PCR 
 Clones of thioredoxin reductase (pMPTRRA, B, C and D) were obtained from Miss M.M 
Photolo (Genetics, UKZN). These clones had been sequenced confirming that they were 
native TRR1. These were then tested to confirm the presence of the TRR1 gene by performing 
a colony PCR (Section 2.6.10) using yeast TRR1 specific primers, 5'-
AGCCATATGGTTCACAACAAAGTTAC-3' and 5'- ACGAAGCTTATTCTAGGGAAGT 
TAAGT-3' (NdeI and HindIII sites are underlined, respectively). The PCR reaction mixture 
consisted of Taq
TM
 DNA polymerase (0.625 U), reaction buffer (1X), a dNTP mix (0.2 mM), 
the forward and reverse primers (250 nM each) and DNA (0.01-1 µg) in 25 µl. The following 
PCR cycling conditions were used: 94°C, 1 min (initial denaturation); 94°C, 30 sec; 46°C, 
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30 sec; 72°C, 1 min (35 cycles) and a final extension at 72°C, 5 min. For all PCR 
experiments a no template control was included in order to check for contamination and the 
PCR products were analyzed by gel electrophoresis (90 V). 
 
2.7.2 Induction and expression 
 Protein expression of the pET28a clones (pMPTRRA, B, C, D) was induced as described 
in Section 2.6.13. Optimization of protein expression was conducted with samples being 
taken every 60 minutes for 6 hours and an OD600 being measured. These samples were 
centrifuged (12,000 × g, 10 min, 4°C) and re-suspended in water to a final OD600 of 10. An 
equal volume of 2 × sample buffer (125 mM Tris-HCl, 4% (m/v) SDS, 20% (v/v) glycerol, 
10% (v/v) mercaptoethanol, 0.01% (m/v) bromophenol blue, pH 6.8) was added to 20 µl of 
the re-suspended samples and the samples were analyzed by SDS-PAGE (Section 2.3). The 
cells were then sonicated, centrifuged (15,000 × g, 20 min, 4°C) and thereafter the 
supernatant was subjected to the DTNB activity assay (Section 2.5.1) (Lim and Lim, 1995). 
The activity of each sample was calculated and this was used to determine the optimal 
expression time for purification. 
 
2.8 Recombinant purification of Trx and thioredoxin reductase 
 
2.8.1 Preparation of Trx and thioredoxin reductase crude extract for purification 
 To purify recombinant proteins, transformed E. coli (DE3) cells containing the appropriate 
plasmid were cultured in LB media (30 µg/ml of kanamycin) until an OD600 (0.6-0.7) was 
reached. Protein expression was induced by adding IPTG (final concentration 0.5 mM) and 
thereafter the Trx cultures were incubated at 37°C in a shaking water bath for 6 hours whilst 
the thioredoxin reductase cultures were incubated for 1 hour. Cells were harvested by 
centrifugation (12,000 x g, 10 min, 4°C), resuspended in 10 volumes of extraction buffer 
(20 mM Tris-HCl (pH 7.5), 10 mM NaCl, 1 mM EDTA, 0.2 mM AEBSF and 5 mM DTT) 
and thereafter disrupted by sonication for 5 min. The samples were then centrifuged 
(12,000 x g, 30 min, 4°C) and the Trx containing supernatant was heat-treated (75°C, 30 min) 
followed by centrifugation (12,000 x g, 30 min, 4°C). The heat treatment step was omitted for 
thioredoxin reductase as this protein was not heat stable. The final supernatant of each protein 
was used as crude extract in Ni-NTA affinity purification.  
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2.8.2 Ni-NTA affinity purification 
 Ni-NTA agarose beads (2 ml) were packed into a column (2 ml bed volume, 0.8 x 4 cm), 
equilibrated with 5 volumes equilibration buffer (0.02 M imidazole, 0.5 M NaCl, 
0.001 M mercaptoethanol, 0.02 M Tris-HCl (pH 8.0)) and thereafter incubated with the 
appropriate crude extract (4°C, 16 hours) in a Revolver™ 360° Sample Mixer. The unbound 
fraction was eluted by gravity and the resin was washed with 10 volumes of wash buffer 
(0.5 M NaCl, 0.02 M Tris-HCl (pH 8.0)). Two volumes of elution buffer (0.25 M imidazole, 
0.5 M NaCl, 0.02 M Tris-HCl (pH 8.0)) was incubated with the resin (4°C, 30 min) and 
thereafter the bound protein was eluted. All fractions were analyzed by SDS-PAGE 
(Section 2.6.14) and the concentration of the purified proteins were determined using the 









, respectively). The resin was then washed with 0.5 M NaOH for 30 min and 
stored in 30% (v/v) ethanol at 4°C. When the resin changed from light-blue to brownish grey, 
it was regenerated according to the manufacturer‟s instructions.  
 
2.8.3 Concentration of protein samples  
 Dilute protein samples were concentrated prior to kinetic analysis by dialysis. Trx and 
thioredoxin reductase samples were placed in dialysis tubing with a cut-off of 3.5 kDa and 




2.9.1 Developing a cheaper and faster Trx activity assay 
 The development of an inexpensive and rapid assay for Trx activity was necessary for the 
screening of crude fractions during the purification procedure. To develop this assay, various 
assay conditions were tested as shown below (Table 2.2), using the same source of crude 
extract. 
 
 Assays 1-3 showed no activity for Trx and changes in the reagent concentrations had no 
effect on the rates observed in these 3 assays (Table 2.2). An unexpected result observed was 
the lack of activity when using potassium phosphate buffer at pH 6.5 as this pH was expected 
to increase the sensitivity of the assay due to the lower solubility of reduced insulin at this pH 
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value (Arnér and Holmgren, 2000a). In fact, it was evident that the DTT-dependent reduction 
of insulin in the control reaction occurred at a faster rate (Section 2.4.1) and these assay 
conditions were not suitable for the purpose of this study.  
 
Assay 4 involved a 20 min incubation of all the components of the assay prior to absorbance 
readings being taken and the reduction of insulin was observed (Sigma-Aldrich, 1994). It was 
unclear whether the rate obtained was due to a change in the pH of the potassium phosphate 
buffer (pH 6.5 to pH 7.0) (Table 2.2) or the extended incubation period prior to readings 
being taken. While a rate was observed, the longer assay posed a problem as this was time 
consuming for a preparative assay. To minimize the time needed to complete the assay, Trx 
was reduced by preincubation with DTT for 10 min at 25°C prior to the start of the reaction 
(Table 2.2, Assay 5) and the rate observed when using this assay was the highest of all the 
assays. Thus, the inclusion of a simple preincubation step, allowed for an assay that was 
relatively cheap and faster than published assays for Trx.  
 
2.9.2 The development of the thioredoxin reductase assay 
 The reduction of DTNB, a generic disulfide substrate, was used to measure thioredoxin 
reductase activity by the change in absorbance at 412 nm. Various published methods were 
attempted to obtain a feasible assay (Table 2.3) and all the assays were performed in 
duplicate with the same crude extract source.  It was evident that while both Assay 1 and 2 
could be used to determine the activity of thioredoxin reductase based on the reduction of 
DTNB (Table 2.3), the inclusion of NaCl in the assay dramatically increased the rate of DTNB 



























  Buffer (pH 6.5) 
(mM) 
Buffer (pH 7.0) 
(mM) 




100 - 2 0.13 0.33 20 0 
2 (Arnér and 
Holmgren, 
2000a) 
100 - 2 0.13 1 20 0 
3 (Holmgren, 
1979b) 




- 63 2 0.01 1 22 1.01 ± 0.0024 





The assays used in this study were modified versions of the assays obtained from the references given. 
b
 Total time required before measurement could begin. 
c
 The same crude extract was used for all the assays tested. Assays were performed in duplicate.
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1 (Arnér and 
Holmgren, 
2000a) 
- 58 - 5 0.3 0.128 ± 0 
 
2 (Štefanková 
et al., 2006) 
- - 100 1 0.5 0.0622 ± 0 
 









The assays used in this study were modified versions of the assays obtained from the references given. 
b 
The same crude extract was used for all the assays tested. 
     
c 
The buffer used in Assay 3 was Tris-HCl (pH 8.0). 
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2.9.3 The successful cloning and expression of TRX1 
 Genomic DNA was successfully isolated from S. cerevisiae using the Bust „N Grab 
method (Figure 2.1 A) (Harju et al., 2004) and PCR amplification of the TRX1 gene was 
performed using this DNA as a template with TRX1 specific primers (Figure 2.1 B). Upon 
completion of the PCR reaction, the amplicons were gel purified (Figure 2.1 C), ligated to the 
pTZ57R/T vector using the InsTAclone
TM
 PCR cloning kit and transformed into E. coli 
JM109 cells to yield three clones. Plasmid DNA from these clones, pTrxA, pTrxB and 
pTrxC, was isolated using a mini-prep procedure and linear, nicked and closed coiled circular 
plasmid forms were obtained (Figure 2.2 A). The identities of the clones were confirmed by 
performing a single restriction digestion with BamHI to linearize the plasmid DNA (Figure 
2.2 B). The size of the bands obtained was 3162 bp which was close to the expected size of 
3211 bp. To further confirm that the pTrxA-C clones contained the TRX1 fragment, a PCR 
was performed using the plasmid DNA as a template. The amplicons (316 bp) obtained 
clearly showed that TRX1 was present in the pTrxA-C vectors (Figure 2.2 C). Bands 
appearing higher up are due to the plasmid template in the reaction. A final confirmation was 
achieved by digesting the pTrxA-C vectors with HindIII and NdeI to liberate the TRX1 
fragment (Figure 2.2 D). Both Molecular weight marker XIV and Molecular weight marker 
III were loaded so as to size the TRX1 fragments and the restricted vectors, respectively.  
 
 pET28a was isolated from E. coli BL21 (DE3) cells using the standard mini-prep 
procedure (Figure 2.3 A) and a double digestion with NdeI and HindIII was performed 































Figure 2.1 Genomic DNA isolation and PCR amplification of the TRX1 gene. Genomic 
DNA was isolated from S. cerevisiae using the Bust „n Grab procedure (Harju et al., 2004) 
(A). PCR of the DNA was undertaken using TRX1-specific primers (B). The PCR product 
was gel purified using the Fermentas gel purification kit (C). The gels have been cropped to 




MWM          






      Genomic DNA 
C 
                        Gel purified TRX1 
                PCR product 









































































                              Undigested 
MWM               Double   MWM 














Figure 2.2 Confirming that the pTZ57R/T clones contained TRX1. pTZ57R/T DNA was 
isolated from E. coli JM109 cells using a standard mini-prep procedure a was restricted with 
BamHI to linearize the plasmid (B). In addition, PCR of the plasmid DNA was undertaken 
using TRX1-specific primers to confirm the presence of the insert (C). Restriction digestion of 
the cloning vector pTZ57R/T-TRX1 showing the release of the TRX1 fragment (D). Some 
gels have been cropped to fit the figures into this thesis but no other bands were observed in 














Figure 2.3 pET28a expression vector isolation and restriction endonuclease digestion. 
pET28a was isolated from E. coli BL21 (DE3) cells using a standard mini-prep procedure 
(A). Restriction digestion of the expression vector (B). The gels have been cropped to fit the 
figures into this thesis but no other bands were observed in the non-MWM lanes.  
  
 The restriction digested pET28a and the liberated TRX1 fragment were both gel purified 
using a Thermoscientific Gel Extraction Kit. The gel-extracted TRX1 fragment and restricted 
pET28a expression vector were subsequently ligated, transformed into E. coli BL21 (DE3) 
cells and a mini-prep was performed to isolate the plasmid DNA (Figure 2.4 A). A PCR was 
performed on the mini-prep to verify the success of the transformation (Figure 2.4 B). The 
band sizes of the mini-prep PCR (316 bp) indicated that TRX1 was successfully cloned into 
the pET28a expression vector. A single restriction digest was performed on the 
pLPTrxA/B/C clones using HindIII and the resulting band size (5623 bp), which was very 
close to the expected band size (5,620 bp), indicated that the transformation was successful 
(Figure 2.4 C). To further confirm a successful transformation the pLPTrxA/B/C clones were 
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Figure 2.4 Transformation of E. coli BL21 (DE3) with pLPTrxA/B/C. pLPTrxA/B/C 
DNA was isolated from E. coli BL21 (DE3) cells using a standard mini-prep procedure (A). 
PCR performed on pLPTrxA/B/C clones to verify success of transformation (B). Single 
restriction digestion of pLPTrxA/B/C clones was undertaken with HindIII to size the clones 
(C) and double digestion with HindIII and NdeI was undertaken to release the TRX1 gene 
(D). The gels have been cropped to fit the figures into this thesis but no other bands were 
observed in the non-MWM lanes.  
 
 The pLPTrxA/B/C clones were subsequently sequenced (Central Analytical Facilities, 
Stellenbosch University) in both directions and the sequencing traces were also manually 
evaluated. The sequences were aligned to the TRX1 sequence from the SGD 
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Figure 2.5 Alignment of the pLPTrxA/B/C (A) promoter sequences and (B) terminator 
sequences with the TRX1 sequence and reverse complement of the TRX1 sequence from 
S. cerevisiae (NCBI Reference Sequence: NC_001144.5), respectively. Identical residues 
are denoted with an asterisk. The overall percentage identity between each promoter and 






Sequence analysis revealed that the TRX1 gene was a successfully cloned (Figure 2.5) and 
these clones could be used for expression. To determine whether Trx could be successfully 
expressed by the pLPTrxA/B/C clones as well as to determine the optimal induction time for 
harvesting Trx, the clones were induced for a number of time points (2-19 hours) and 
analyzed by SDS-PAGE (Figure 2.6 A) and activity assays (Figure 2.6 B) at each time point 
was performed. The protein was successfully expressed as the calculated band size was 
12 kDa for Trx. Optimum expression (Figure 2.6 A) and maximum specific activity 
(Figure 2.6 B) was observed after inducing the cells for 6 hours and this time point was 





















Figure 2.6 Expression and specific activity of TRX1 at various time points (2-19 hours). 
Recombinant TRX1 expression was induced with 0.5 mM IPTG for 0-19 hours and analyzed 
by SDS-PAGE (A). The specific activity of induced fractions (B) was also determined. 
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2.9.4 The purification of recombinant thioredoxin reductase and Trx by affinity 
chromatography 
 The pMPTRRA/B/C/D clones were obtained from Miss M.M Photolo (Genetics, UKZN) 
and were evaluated by colony PCR to ensure that the TRR1 gene was present. Upon 
confirmation (data not shown), these clones were IPTG-induced at different time intervals in 
order to confirm that this protein could be expressed by these clones. The protein was 
expressed successfully with an induced band at a calculated size of 36 kDa which was very 
close to the expected size of 35 kDa (Figure 2.7 A). Once successful induction was observed, 
it was necessary to determine the optimal induction time for harvesting thioredoxin reductase. 
Cultures were IPTG-induced for a number of time points (1-6 hours) (Figure 2.7 A) and 
assayed for activity (Figure 2.7 B). Over the time points tested, optimum expression 
(Figure 2.7 A) and maximum specific activity (Figure 2.7 B) were observed after inducing 
the cells for 1 hour and this time point was used for the purification of thioredoxin reductase. 
The gel has been cropped to fit the figure into this thesis but no other bands were observed in 
the non-MWM lanes. 
 
 To purify the recombinant proteins, transformed E. coli (DE3) cells containing the 
appropriate plasmid were cultured and induced with IPTG for the appropriate time. These 
fractions were then treated as described above (Section 2.8.1) and used as crude extract for 
nickel affinity purification. The presence of single bands in the latter lanes indicated a 






































































Figure 2.7 Induction of TRR1. Recombinant TRR1 expression was induced with 
0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for various time intervals (0-6 hours) 
and analyzed by SDS-PAGE (A) and the DTNB reduction assay (B). Duplicate biological 
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Figure 2.8 Ni-NTA affinity purification of recombinant TRX1 (A) and TRR1 (B). TRX1 
expression was induced for 6 hours and the cells processed as described in Section 2.8.1 to 
yield pure TRX1 (A). TRR1 was induced for 1 hour and the cells processed as described in 
Section 2.8.1 to yield pure TRR1 (B). The gels were stained with Coomassie blue. 
 
2.10 Discussion 
 To purify Trx and thioredoxin reductase, a number of hurdles had to be overcome. Firstly, 
a major problem with assaying coupled systems is that at least one of the components must be 
readily available. Both Trx and thioredoxin reductase are extremely expensive and therefore 
purchasing these proteins was not an option. For this reason, it was necessary to develop 
assays for each protein that did not require its counterpart. 
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 The standard insulin assay (Arnér and Holmgren, 2000a) for determining the activity of 
thioredoxin is both time-consuming and costly which makes it impractical for protein 
isolations. We developed an assay based on the DTT-dependent reduction of insulin by Trx 
(Holmgren, 1979b) and found that DTT could indeed be used instead of thioredoxin 
reductase which provided a considerable saving. Further, the inclusion of a preincubation step 
with DTT increased the rate of reduction and the assay could be completed in a shorter time 
interval (10 min) (Table 2.2). This assay was used for the subsequent purification steps. 
  
 Thioredoxin, the natural substrate of thioredoxin reductase is also very expensive and 
difficult to obtain so the activity of thioredoxin reductase is usually assayed using 5,5'-
dithiobis-2-nitrobenzoic acid (DTNB). For this study, assays described by Arner and 
Holmgren (2000a) as well as Štefanková et al. (2006) were attempted. These assays enabled 
the detection of thioredoxin reductase present in crude extracts in the absence of Trx, thereby 
greatly reducing the cost associated with the native assay. However, the rates obtained 
through both methods were not satisfactory (Table 2.3) and could have been caused by the 
NADPH-dependent inactivation of thioredoxin reductase (Štefanková et al., 2006). However, 
by including univalent cations (Lim and Lim, 1995), the sensitivity of the assay was 
significantly increased compared to the assays that lacked these cations (Table 2.3).  
  
 Once activity assays for both Trx and thioredoxin reductase were developed, the next step 
involved the recombinant expression and purification of both proteins. Genomic DNA from 
S. cerevisiae was isolated and the TRX1 gene was amplified and cloned into the pTZ57R/T 
cloning vector and then subcloned into the pET28a expression vector. The successful induction 
of Trx expression (Figure 2.6) and the 100% similarity observed with the sequence data 
alignments (Figure 2.5) showed that TRX1 was successfully cloned and expressed.  
 
 To obtain thioredoxin reductase, clones were tested and found to contain the TRR1 gene. 
Thioredoxin reductase expression was induced (Figure 2.7) and both thioredoxin and 
thioredoxin reductase were successfully purified by nickel affinity chromatography 
(Figure 2.8). The purified thioredoxin system was then concentrated as described in Section 





Chapter 3: The thioredoxin system and not the Michaelis-
Menten equation should be fitted to substrate saturation datasets 





Several substrates such as 5,5'-dithiobis (2-nitrobenzoic acid) (DTNB) (Akif et al., 2008, 
Mark and Richardson, 1976) and fluorescently labelled proteins (Heuck and Wolosiuk, 
1997b) have been used to measure thioredoxin activity but insulin with a single intrachain 
and two interchain disulfide bonds (Li et al., 2012) still remains the most popular substrate 
for characterizing thioredoxin activity in vitro (Holmgren, 1979a). This assay involves either 
turbidimetrically monitoring the aggregation of the free B-chain resulting from the reduction 
of insulin by thioredoxin (Holmgren, 1979b) or by coupling the reaction to NADPH 
oxidation (Scheme I) (Holmgren, 1979a).  
 
Scheme I: Thioredoxin enzyme model 
     +      
  
→     +        (3.1) 
       (  ) +      →        (   ) +        (3.2) 
Net:      +         (  )
   
→     +         (   ) (3.3) 
where TrxSS and TrxSH represent reduced and oxidized thioredoxin respectively and TR 
represents thioredoxin reductase. 
 
Increases in the insulin concentration result in a classical substrate saturation profile and 
Michaelis-Menten parameters have consequently been assigned to thioredoxin (Holmgren, 
1979a, Obiero et al., 2010, Maeda et al., 2010, Bao et al., 2009, Chen et al., 2014, Juttner et 
al., 2000). Despite mammalian insulin not being the physiological substrate for all the 
thioredoxins characterized with this assay, it is readily reduced by most thioredoxins. This 
common substrate therefore allows for semi-quantitative kinetic comparisons between 
different thioredoxins. However, in many of these studies it was not always clear whether 
                                                 
1
Padayachee, L. & Pillay, C. S. 2016. The thioredoxin system and not the Michaelis–Menten equation should be 
fitted to substrate saturation datasets from the thioredoxin insulin assay. Redox Report, 21, 170-179. 
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thioredoxin reduction or thioredoxin oxidation was the rate-limiting step in the assay 
(Scheme I). The activities of other redoxins (glutaredoxins and peroxiredoxins) have also 
been described using Michaelis–Menten kinetic parameters (see for example (Akerman and 
Müller, 2003, Akerman and Müller, 2005, Peltoniemi et al., 2006)).  
 
There have been a number of conflicting reports on the interpretation of the plots 
generated in these experiments (Mashamaite et al., 2015). For example, unlike most 
enzymes, thioredoxin is inactivated by its substrate and requires thioredoxin reductase to 
regenerate it. Further, in the original description of the thioredoxin insulin assay, it appeared 
that varying concentrations of thioredoxin reductase in the assay led to changes in the 
observed turnover number for thioredoxin activity (Holmgren, 1979a). Moreover, in other 
studies, oxidized and reduced thioredoxins have been detected in vivo (Trotter and Grant, 
2003, Watson et al., 2004), suggesting that the thioredoxin redox couple‟s activity should be 
characterized by redox potentials and not enzyme kinetic parameters. For computational 
systems biology studies, in particular, these discrepancies posed a serious limitation as it was 
not clear whether thioredoxin should appear in the stoichiometric matrix or rate vector of the 
equation describing the kinetic model of the system (Pillay et al., 2013).  
 
Using a computational model, it was suggested that these disparate observations could be 
reconciled by proposing that the saturation observed in the insulin assay was due to a 
limitation in the thioredoxin redox cycle (Pillay et al., 2009). As the insulin concentration 
was increased, thioredoxin oxidation increased and the activity of the thioredoxin reduction 
reaction correspondingly increased until it was limited by the availability of oxidized 
thioredoxin or by saturation of the thioredoxin reductase, or both. This in turn limited the 
reduced thioredoxin available for insulin reduction and the flux through the system saturated 
(Pillay et al., 2009). It was further proposed that mass-action kinetics appeared to be 
sufficient to describe insulin reduction by thioredoxin. Substrate reduction by thioredoxin 
proceeds via the formation of a mixed-disulfide complex between the redoxin and its 
substrate (Wynn et al., 1995). Once formed, the breakdown of these redoxin–substrate 
complexes is highly favorable and therefore the intermediate steps involving the mixed-
disulfide complex were not explicitly modeled but were instead combined into a single 
second-order rate constant (Pillay et al., 2009). The validity of this simplification was tested 
by fitting a computational model of the E. coli thioredoxin system to a published in vitro 
dataset (Holmgren, 1979a). Collectively, these findings suggested that the kinetic parameters 
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for thioredoxin should be obtained by fitting a kinetic model of the entire thioredoxin system 
(Scheme II) to a given substrate saturation dataset and that mass-action kinetics could 
adequately describe insulin reduction.  
 
Scheme II: Thioredoxin redox couple model 
     +      
  
→     +        (3.4) 
       (  ) +      →        (   ) +       (3.5) 
 
A number of systems biology studies have since used this approach to describe 
thioredoxin activity in large-scale kinetic models (Pillay et al., 2011, Adimora et al., 2010, 
Benfeitas et al., 2014). However, Lin (2010) found a discrepancy between the model output 
and the insulin reduction profile obtained when using a minimal model (Pillay et al., 2009) of 
the yeast thioredoxin system (equation 3.6): 
 
  =
(              )       
  
  
              
 (3.6) 
 
In this minimal description of the entire thioredoxin system (Scheme II), the thioredoxin 
reductase reaction was described by mass-action kinetics with a second-order rate constant 
(k1), Trxtot refers to the total thioredoxin concentration and insulin reduction was also 
described by a second-order rate constant (k2). Note that equation (3.6) has the same form as 
the Michaelis-Menten equation with a Vmax described by k1.NADPH.trxtot, an apparent kcat 
described by k1.NADPH and an apparent Km described by k1.NADPH/k2; therefore the ratio 
kcat/Km is equal to k2, the true rate constant for insulin reduction (Pillay et al., 2009).  
 
As thioredoxin reductase is fully saturated by NADPH in the insulin assay, the flux 
through the system is effectively zero-order with respect to the NADPH concentration and 
therefore equation (3.6) has limited value for fitting datasets under these conditions. Lin 
(2010) nonetheless proposed that thioredoxin was indeed an enzyme whose activity could 
presumably be described with Michaelis-Menten parameters. Thus, it is not clear whether 
substrate saturation datasets from the thioredoxin insulin assay should be fitted with the 
Michaelis-Menten equation or whether they should be fitted with the entire thioredoxin 
system (Scheme II). Therefore computational modeling and in vitro kinetic assays of the 
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thioredoxin insulin system were employed to determine which of these approaches should be 
used to characterize thioredoxin activity. 
 
3.2 Materials  
Trichloroacetic acid (TCA) and methoxypolyethylene glycol maleimide (PEG-maleimide 
Mn 5,000) were obtained from Sigma (Capital Labs, Johannesburg, South Africa) and all 
other common chemicals were from Saarchem/Merck (Johannesburg, South Africa) and were 
of the highest purity available.  
 
3.3 Methods 
3.3.1 Kinetic modeling 
Kinetic modeling experiments were carried out using the open source Python Simulator 
for Cellular Systems (PySCeS) modeling software (Olivier et al., 2005) 
(http://pysces.sourceforge.net) as described previously (Pillay et al., 2011). Detailed models 
were created to analyze the E. coli and S. cerevisiae thioredoxin systems and were 
parameterized with realistic parameter sets (Table 3.1) which were obtained from either 
primary literature sources, the BRENDA kinetic parameter database (Chang et al., 2009) 
(http://www.brenda-enzymes.info), or from the in vitro kinetic assays performed. In these 
models, thioredoxin reductase was modeled with a two-substrate Michaelis-Menten kinetic 
expression and insulin reduction was modeled with mass-action kinetics as described 
previously (Pillay et al., 2009). Kinetic models of the entire thioredoxin system or the 
Michaelis-Menten equation were fitted to in vitro datasets using non-linear least squares 
regression with the Levenberg–Marquardt algorithm (Pillay et al., 2009). The PySCeS 






Table 3.1 Kinetic parameters and species concentrations used for building 
computational models of the E. coli and baker’s yeast thioredoxin systems. 
Species E. coli S. cerevisiae Reference 
 (μM) (μM)  
NADPH
 
400 400 Holmgren (1979a), this study 
NADP 1.0 1.0 Holmgren (1979a), this study 
TrxSS 0.05 0.75 Holmgren (1979a), this study 
TrxSH 0.05 0.75 Holmgren (1979a), this study 
Insulin (oxidized) 30 20 Holmgren (1979a), this study 
Insulin (reduced) 1.0 1.0  












 Gleason et al., (1990), Chang et 
al., (2009)  
Knadph 1.2 μM 1.2 μM Williams (1976)  
Ktrxss 2.8 μM 4.4 μM Williams (1976), Speranza et al., 
(1973)  





 0.003 μM. s
-1
 Pillay et al., (2009), this study 
 
3.3.2 Thioredoxin insulin reduction assay 
A number of variations of coupled redoxin assays have been presented in the literature. In 
some assays, NADPH oxidation was monitored by a decrease in absorbance at 340 nm 
starting at a positive value (Baker et al., 2001, Si et al., 2014), typically 0.9 for an NADPH 
concentration of 150 µM (Nelson and Parsonage, 2011), while in other assays, a decrease in 
absorbance from the blank was monitored (Arnér and Holmgren, 2000a). To compare these 
methods, insulin reduction was undertaken at 25ºC in a final volume of 1 ml in a 100 mM 
potassium phosphate (pH 7.0) buffer containing EDTA (2 mM), NADPH (0.15 or 0.4 mM), 
insulin (20-160 µM), thioredoxin (1.5 µM) and thioredoxin reductase (0.05 µM). NADPH 
oxidation was monitored at 340 nm in a UV-1800 Shimadzu Spectrophotometer and 
depending on the assay being tested, a sample without the addition of either NADPH or 
thioredoxin reductase was used as the reference cuvette. To determine the effect of 
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thioredoxin reductase on the rate of insulin reduction, the assay was undertaken as described 
above with NADPH (0.4 mM), insulin (20-200 µM) and varying thioredoxin reductase 
concentrations (0.05-0.25 µM). Insulin reduction activity was defined as the concentration of 





. Absorbance measurements were taken for at least five minutes, although 
initial studies showed that the system remained in steady state well beyond this assay period 
during which no significant insulin precipitation occurred. All assays were undertaken in 
triplicate and the data obtained were plotted as a mean ± standard error. 
 
3.3.3 Determination of the redox state of Trx 
The redox state of thioredoxin was determined using the method described by Hugo et al. 
(2014).  The steady state insulin reduction assay components were added directly into 
100% (w/v) ice-cold TCA (100 µl) and incubated on ice for 30 min. The TCA-treated 
samples were then transferred to an Amicon® Ultra 2 ml centrifugal filter (10,000 NMWL) 
and centrifuged (7,500 x g, 20 min, 4°C) to remove the insulin. As a control to ensure that no 
protein was lost during centrifugation, the eluate was assayed for thioredoxin and thioredoxin 
reductase activity and was also tested by SDS-PAGE. The remaining concentrate was 
transferred and centrifuged (22,065 x g, 40 min, 4°C). The resulting pellet was washed with 
ice-cold acetone (100 µl), dried at 37°C and resuspended in 50 µl of alkylation buffer 
(3 mM PEG-maleimide, 50 mM Tris (pH 7.5), 10 mM EDTA (pH 8.0), 0.1% (m/v) SDS). 
After a 45 min incubation period at 45°C, the alkylated samples were mixed with an equal 
volume of 2 × non-reducing sample buffer (125 mM Tris-HCl, 4% (m/v) SDS, 20% (v/v) 
glycerol, 0.01% (m/v) bromophenol blue, pH 6.8), and then separated by electrophoresis on a 
15% acrylamide Tris-Tricine gel, which was subsequently stained with Coomassie blue. All 
assays were undertaken in triplicate and representative gel images are shown below. As 
migration controls, reduced thioredoxin was obtained by incubating thioredoxin (1.5 µM) 
with DTT (1 mM) at 37°C for 1 hour, while purified thioredoxin served as the oxidized 
control. The control samples were processed for electrophoresis as described above, and as 
expected, the reduced form of thioredoxin migrated higher on these gels. The intensity ratio 
of the bands was determined with ImageJ (http://imagej.nih.gov/ij/) using the 







3.4.1 Computational models with thioredoxin described either as an enzyme, or as a 
redox couple, have contrasting kinetic properties. 
To determine whether it really mattered if thioredoxin activity was described with 
Michaelis-Menten parameters or with mass-action kinetics, two distinct kinetic models in 
which thioredoxin acts as an enzyme (equation 3.3, Scheme I) or as a redox couple 
(Scheme II) were both fitted to a previously published in vitro insulin reduction dataset 
(Holmgren, 1979a). As mammalian insulin contains three disulfide bonds and reduction was 
followed by NADPH oxidation, it was also important to determine whether it made a 
difference to the fitting results if the insulin or the disulfide bond concentration was 
considered as the „substrate‟ in these experiments. In addition, the computational models 
were used to highlight the key differences between the thioredoxin enzyme and redox couple 
fitting approaches. 
 
Both the Michaelis-Menten equation and the redox couple model showed excellent fits 
(r
2
≥0.996) to the insulin saturation profile (Figure 3.1 A), suggesting that both models were 
apparently consistent with the dataset (Table 3.2). As the redox couple model predicted that 
substrate saturation was due to a limitation in thioredoxin reductase activity, the effect of 
increasing the thioredoxin reductase concentration on the rates within the system was also 
tested. Increasing the thioredoxin reductase concentration increased the insulin reduction rate 
in the thioredoxin redox couple model (Figure 3.1 A), confirming that its activity was 
limiting in this system. Note that in the kinetic model, thioredoxin reductase was described 
with Michaelis-Menten kinetics, which would not be accurate at thioredoxin and thioredoxin 
reductase concentrations of 1.5 and 0.1 µM respectively, as the thioredoxin concentration was 
only fifteen-fold larger than the thioredoxin reductase concentration. Nonetheless, the fitted 
second-order rate constant obtained over a range of thioredoxin reductase concentrations 







Figure 3.1 The Michaelis-Menten equation and the thioredoxin redox couple model 
both fit an in vitro insulin reduction dataset (Holmgren, 1979a) but the resulting kinetic 
models show distinct responses to thioredoxin reductase concentration and substrate 
saturation. In (A) the Michaelis-Menten equation and the thioredoxin redox couple kinetic 
model (black line) both showed excellent fits (r
2
≥0.996) to an insulin substrate saturation 
dataset (●). Increasing the thioredoxin reductase concentration (0.05 µM) in the thioredoxin 
redox couple model to 0.15 (blue) or 0.25 µM (green) increased the flux within the system at 
a given insulin concentration. Substrate saturation (black) within a fitted thioredoxin redox 
couple model (0.05 µM thioredoxin reductase) was accompanied by the redistribution of 
thioredoxin from its reduced (blue) to oxidized (red) form (B). In (C) disulfide bond rather 
than insulin concentration was used to determine the kinetic parameters for thioredoxin-





In contrast, the apparent Michaelis-Menten parameters of the system varied significantly 
at different thioredoxin reductase concentrations, although the kcat/Km compared favorably to 
the second-order rate constant obtained by fitting the redox couple model (Table 3.2, 
cf. equation 3.6). Thus, if correct, the redox couple model (Scheme II) predicted that the 
apparent Michaelis-Menten parameters for the system would vary depending on the 
thioredoxin reductase concentration used in the experiment, while fitting of the entire system 
should yield a consistent second-order rate constant over a range of thioredoxin reductase 
concentrations. Conversely, if thioredoxin was indeed limiting in the system and responsible 
for the substrate saturation profile, increasing thioredoxin reductase should have negligible 
effects on the insulin reduction rate and the Michaelis-Menten parameters obtained 
(Holmgren, 1979a). An additional distinguishing prediction made by these simulations was 
that substrate saturation in the redox couple model was accompanied by the progressive 
redistribution of the thioredoxin moiety into its oxidized form (Figure 3.1 B). In contrast, if 
thioredoxin was described as an enzyme, there should be no net change in the steady-state 
redox state of thioredoxin (equation 3.3, Scheme I). 
 
Models using the disulfide bond concentration as the „substrate‟ were also developed and 
analyzed (Figure 3.1 C) to determine if it made a difference to the kinetic rate parameters 
obtained in the fitting experiments. Not surprisingly, it was found that the mass-action rate 
constants (k2) obtained for the disulfide bond reduction were lower than the rate constants for 
insulin reduction but again showed a good correlation with the kcat/Km values obtained when 
using this substrate (Table S1). A limitation with such an analysis is that it assumes that all 
three disulfide bonds in insulin are equally accessible. However, data from insulin 
aggregation studies have shown that the porcine insulin intrachain A6-A11 and interchain 
A7-B7 disulfide bonds were more accessible to reduction than the buried A20-B19 disulfide 
bond (Li et al., 2012). Thus, the second-order rate constant obtained from this analysis and 
indeed the analysis with insulin as the substrate (above) describes a complex set of reduction 
events within a single aggregated parameter. As a final control, the redox couple model was 
modified to determine if another rate expression could be used for the insulin reduction 
reaction (equation 3.5) in these fitting experiments. This reaction was therefore described 
with reversible mass-action, Hill and Michaelis-Menten kinetics, but appreciably poorer fits 
of the data (data not shown) were obtained, suggesting that irreversible mass-action kinetics 
were apparently sufficient to describe the reduction of insulin for the concentrations of 
thioredoxin reductase tested. As these computational modeling observations could be directly 
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tested in vitro, the thioredoxin system was isolated from S. cerevisiae and analyzed using the 
insulin reduction assay. 
 
Table 3.2 The Michaelis-Menten parameters and second-order rate constants (k2) for 
insulin reduction from computational modeling of the E. coli thioredoxin system at 
varying thioredoxin reductase (TR) concentrations. 
* As the standard errors for the kcat and Km values were less than 5% of the total, the 
standard errors for the kcat/ Km values were not considered. 
 
Table 3.3 The Michaelis-Menten parameters and second-order rate constants (k2) for 
insulin reduction by the baker’s yeast thioredoxin system at varying thioredoxin 
reductase (TR) concentrations. 
* As the standard errors for the kcat and Km values were less than 5% of the total, the 
standard errors for the kcat/ Km values were not considered. 
 
3.4.2 Assay of the yeast thioredoxin system 
 The insulin reduction assay with the oxidation of NADPH was used to determine the 
kinetic parameters for the reaction schemes (I and II). Two variations of the coupling assay to 
NADPH have been presented in the literature, where NADPH oxidation was monitored by a 
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(µM) 





















0.1 11.52 ± 1.12 0.75 ± 0.02 0.06 0.996 0.06 ± 0.005 0.997 
0.5 57.37 ± 1.41 3.88 ± 0.04 0.06 0.999 0.07 ± 0.001 0.999 
1.0 110.09 ± 4.27 7.53 ± 0.17 0.06 0.999 0.07 ± 0.001 0.999 
























Km ± SE* 
(µM) 





















0.05 38.21 ± 5.85 0.11 ± 0.01 0.003 0.97 0.003 ± 0.0003 0.97 
0.15 25.81 ± 6.74 0.15 ± 0.01 0.006 0.92 0.005 ± 0.0008 0.94 





decrease in absorbance at 340 nm starting at a positive absorbance value (Baker et al., 2001, 
Si et al., 2014) or by a decrease in absorbance from the blank (Arnér and Holmgren, 2000a). 
Both these methods (Figure 3.2) were compared and no differences in the rates obtained over 
a range of NADPH concentrations (0.15-0.4 mM) were found. However, the former assay 




Figure 3.2 Similar rates were obtained when the thioredoxin insulin assay was initiated 
with thioredoxin reductase or NAPDH. Insulin reduction by the thioredoxin system was 
initiated with either thioredoxin reductase (A) or NADPH (B) and a decrease in absorbance 
was monitored over negative and positive scales, respectively. The assay contained insulin 
(80 µM), thioredoxin reductase (0.05 µM), thioredoxin (1.5 µM) and NADPH (150 µM) and 
was performed in duplicate. 
 
3.4.3 Thioredoxin reductase activity is limiting in the insulin reduction assay 
According to the thioredoxin redox couple model, increases in the thioredoxin reductase 
concentration should increase the flux through the system (Figure 3.1 A). To test this 
prediction, the rate of NADPH oxidation was measured at varying concentrations of insulin 
(20-200 µM) and yeast thioredoxin reductase (0.05-0.25 µM). As the concentration of 
thioredoxin reductase was increased, there was a corresponding increase in the flux through 
the system (Figure 3.3) supporting the thioredoxin redox couple model (Scheme II) and 
showing that the saturation observed in this assay was due to an apparent limitation in 







Figure 3.3 Changing the thioredoxin reductase concentration altered the kinetic profile 
and parameters obtained with the yeast thioredoxin insulin reduction assay. The flux 
obtained for a given insulin concentration increased as the thioredoxin reductase 
concentration was increased over the range 0.05 (●), 0.15 (■) and 0.25 µM (♦). The 
Michaelis-Menten equation and the redox couple model were both fitted to these datasets 
using either insulin concentration (A) or the disulfide bond concentration (B). All assays were 




The computational modeling also predicted that changes in the thioredoxin reductase 
concentration would cause changes in the Michaelis-Menten parameters if its activity was 
limiting in the assay (Table 3.1). Therefore the effect of changing the thioredoxin reductase 
concentration on the Michaelis-Menten parameters (Scheme I) and on the second-order rate 
constant for insulin reduction obtained by fitting the entire thioredoxin system to the 
saturation datasets (Scheme II) was determined. While the Km values remained relatively 
constant, changes in the thioredoxin reductase concentration resulted in changes to the 
apparent kcat values, which was also noted in a previous study (Holmgren, 1979a). In contrast, 
the second-order rate constant for insulin reduction (k2, obtained by fitting the complete 
system) remained relatively constant and, as expected (Table 3.2), showed a good correlation 
with the kcat/Km Michaelis-Menten parameters (Table 3.3). Fitting experiments performed 
with the disulfide bond concentrations rather than the insulin concentrations also resulted in 
different Michaelis-Menten and second-order rate constant parameter values. As with the 
computational modeling studies, there was a good correlation between the k2 and the kcat/Km 
values obtained (Table S1). However, a satisfactory global fit of all the experimental data was 
unobtainable, suggesting that the kinetic model could not completely describe the complex 
set of reduction and aggregation events associated with insulin reduction (Li et al., 2012, 
Zako et al., 2009). 
 
3.4.4 Saturation of the redox cycle and redistribution of the thioredoxin moiety
 
Over the complete range of thioredoxin reductase concentrations tested, increases in the 
insulin concentration resulted in observed substrate saturation. According to the redox couple 
model (Pillay et al., 2009), this would be due to the saturation of the thioredoxin redox cycle 
as thioredoxin reductase activity became limiting and the thioredoxin moiety distributed into 
its oxidized form (Figure 3.1 B). To experimentally verify whether there indeed was a 
redistribution of the oxidized and reduced forms of the thioredoxin moiety, the thioredoxin 
redox state was preserved by rapidly treating the steady-state insulin reduction reactions with 
TCA and alkylating the extracts with PEG-maleimide (Hansen and Winther, 2009). Increases 
in the insulin concentration resulted in the progressive redistribution of the thioredoxin 
moiety into its oxidized form (Figure 3.4), which was consistent with the computational 













Figure 3.4 Substrate saturation is associated with redistribution of the thioredoxin 
moiety into its oxidized form in the insulin reduction assay. Reduced thioredoxin in the 
insulin reduction assay was alkylated with PEG-maleimide. As migration controls, reduced 
thioredoxin was obtained by incubating thioredoxin (1.5 μM) with DTT (1 mM), while 
purified thioredoxin served as the oxidized control. Equal concentrations of the thioredoxin 
test samples were loaded onto the gel and the relative concentration of the oxidized and 
reduced forms of thioredoxin were quantified using ImageJ with the reduced thioredoxin 
control acting as a loading standard (A). The experiment was performed in triplicate over a 
range of thioredoxin reductase concentrations (0.05-0.25 μM) and a representative gel image 
is shown here. To illustrate the reproducibility of the experiment, the mean and the standard 
error values of the oxidized (●) and reduced (●) thioredoxin fractions retrieved from triplicate 





3.5 Discussion  
The insulin reduction assay is one of the most commonly used methods to determine 
thioredoxin activity in vitro, but the classical substrate saturation profile generated with 
increasing insulin concentrations has usually been fitted to the Michaelis-Menten equation 
(Scheme I) (Holmgren, 1979a, Obiero et al., 2010, Maeda et al., 2010, Bao et al., 2009, 
Juttner et al., 2000, Chen et al., 2014), although it was recently proposed that these datasets 
should be fitted to a model of the entire system of reactions (i.e. the redox couple model 
approach, cf. Scheme II) (Pillay et al., 2009). To distinguish between these approaches, a 
computational model of an E. coli thioredoxin system was used which yielded three key 
predictions. If the redox couple model fitting approach were correct, a) the second-order rate 
constant for insulin reduction (k2) would remain constant but the apparent Michaelis-Menten 
parameters would change with varying thioredoxin reductase concentrations (Table 3.2), b) 
thioredoxin reductase activity would be limiting in the system (Figure 3.1 A), and c) the 
thioredoxin moiety would redistribute into its oxidized form with increasing substrate 
concentration (Figure 3.1 B). On the other hand, if fitting with the Michaelis-Menten 
equation (Scheme I) were correct, the thioredoxin reductase concentration would have a 
negligible effect on the rate and Michaelis-Menten parameters for insulin reduction, and 
thioredoxin should remain in its reduced, active enzymatic form with increasing substrate 
concentration.  
 
To test the predictions in vitro the classical insulin reduction assay for thioredoxin activity 
was used (Holmgren, 1979a). The data showed that increasing the thioredoxin reductase 
concentration resulted in an increased flux through the system (Figure 3.3) and also caused a 
significant change to the kcat values while the second-order rate constant for insulin reduction 
(k2) obtained from fitting the redox couple model remained relatively constant over a range of 
thioredoxin reductase concentrations. Further, using an alkylation assay, the steady-state 
oxidation of the thioredoxin moiety was observed with increasing insulin concentrations 
(Figure 3.4). Collectively, the data obtained from the in vitro analysis support the redox 
couple model for saturation in the thioredoxin system and suggest that fitting experiments on 
insulin reduction assay datasets should use models of the entire system of reactions under 
study. A potential limitation of the combined experimental and modeling approach is that it 
might be possible that other kinetic models may also fit these datasets. Therefore a number of 
other rate expressions for insulin reduction (equation 3.5, Scheme II) were tested, but these 
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fitting experiments were unsuccessful. Irreversible mass-action kinetics for thioredoxin-
dependent insulin reduction appeared to be sufficient to describe the data for each 
concentration of thioredoxin reductase used in the experiments. While several studies have 
shown that fitting of other redoxin systems to substrate saturation datasets does indeed yield 
consistent and reproducible parameter sets (Benfeitas et al., 2014, Mashamaite et al., 2015), a 
satisfactory global fit with all the datasets was unobtainable. This result suggests that the 
differences in the kinetic profiles obtained for different thioredoxin reductase concentrations 
could not be completely explained by the computational models, which was not surprising 
given the complex reduction and aggregation kinetics of insulin (Li et al., 2012, Zako et al., 
2009).  
 
The results presented here make two important contributions to our understanding of 
redoxin kinetics and analysis. First, consistent second-order rate constants for thioredoxin-
dependent insulin reduction should be obtainable regardless of the thioredoxin reductase 
concentration used in the assay. A good correlation was noted between the kcat/Km values and 
the second-order rate constant obtained by direct fitting of the entire system (Tables 3.2-3.3). 
Thus, specifically the kcat/Km values (but not all the Michaelis-Menten parameters in general) 
reported for thioredoxin in previous studies (see for example (Holmgren, 1979a, Lin, 2010) 
could still be used in modeling thioredoxin-dependent networks or in the kinetic analysis of 
related reactions such as peroxiredoxin reduction. A second contribution from this study is 
that it provides the first experimental support for the computational and theoretical modeling 
studies that have already used the redox couple approach to develop kinetic models of the 
thioredoxin system in E. coli (Pillay et al., 2011), Schizosaccharomyces pombe (Tomalin et 
al., 2016) as well as the Jurkat-T (Adimora et al., 2010) and red blood cells (Benfeitas et al., 
2014). Further, validation of the approach to characterize thioredoxin activity allowed us to 
confidently use computational models of the thioredoxin system to identify the minimum, 
experimentally tractable, parameter set needed to quantitatively describe the behaviour of this 
system under reductive supply and oxidative demand conditions.  
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Chapter 4: The thioredoxin redox charge as a surrogate 
measure for flux 
 
4.1 Introduction 
The thioredoxin system plays a central role in redox regulation by providing reducing 
equivalents for a diverse range of metabolic, signaling and antioxidant targets (Chapter 1). 
The activity of the thioredoxin system is a function of both the reductive electron supply 
(NADPH, thioredoxin reductase and thioredoxin concentrations) as well as the oxidative 
demand for thioredoxin by its target reactions (Pigiet and Conley, 1977, Das and Das, 2000, 
Mukherjee and Martin, 2008, Holmgren and Lu, 2010, Sengupta and Holmgren, 2012). This 
connectivity within the thioredoxin system allows for a number of important emergent 
properties such as ultrasensitivity and adaptability (Pillay et al., 2011) but poses a significant 
challenge for quantification and several measures have been used to estimate the activity of 
the system in vivo including the thioredoxin and thioredoxin reductase specific activities 
(Lovell et al., 2000) thioredoxin redox potentials (Watson et al., 2003) and redox ratios 
(Nkabyo et al., 2002, Trotter and Grant, 2003, Watson and Jones, 2003). Although these 
measures may be readily obtained through activity assays or redox western blotting (Trotter 
and Grant, 2003, Halvey et al., 2005, Sobhakumari et al., 2012, Ungerstedt et al., 2012), it is 
arguable whether any of these measures provides an accurate quantitative measure of the 
activity of the system. A combination of these measures has consequently been reported for 
thioredoxin/thioredoxin reductase inhibitor studies in vivo (Du et al., 2012, Lu et al., 2013, 
Jortzik et al., 2014). 
 
A system‟s flux represents an integrated outcome of transcript, metabolite and protein 
levels as well as post-translation modifications (Nielsen, 2003) and for the Trx system 
specifically, the flux is also a direct measure of the reductive supply and oxidative demand 
activities on the system (Figure 4.1). While the thioredoxin system flux can be readily 
obtained through spectrophotometry in vitro (Holmgren, 1979a, Arnér and Holmgren, 
2000a), measuring this flux in vivo is significantly challenging although the development of 
redox systems biology approaches has allowed for flux estimation using computational 
models and data-fitting (Sauer, 2006, Adimora et al., 2010, Benfeitas et al., 2014, Tomalin et 
al., 2016). However, even this approach has its limitations as the choice of kinetic 
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expressions for redoxins in these models has been ambiguous which can affect the models‟ 
properties and outputs (Mashamaite et al., 2015, Padayachee and Pillay, 2016, Pillay et al., 
2016). An experimentally tractable surrogate measure for flux would therefore represent a 




Figure 4.1 A model of the E. coli thioredoxin system illustrating the reductive supply 
and oxidative demand activities on the system. The reduction of oxidized thioredoxin 
(TrxSS) is catalyzed by thioredoxin reductase (TR) and NADPH, and in turn reduced 
thioredoxin (TrxSH) serves as an electron donor for the reduction of methionine sulfoxide 
(MetSO) and 3‟-phosphoadenosine-5‟-phosphosulfate (PAPS) by methionine sulfoxide and 
PAPS reductase respectively. Also included is the reduction of the peroxiredoxin (Tpx) by 
thioredoxin and its oxidation by hydrogen peroxide (H2O2) as well as the reduction of protein 




The mechanism of saturation in the thioredoxin system was previously confirmed which 
revealed that increases in thioredoxin substrate concentration leads to an increased flux and 
the concomitant distribution of thioredoxin into its oxidized state (Chapter 3). Changes in the 
thioredoxin redox state therefore correspond to changes in the flux of the thioredoxin system 
and we propose that the thioredoxin redox charge, analogous to the adenylate energy charge 
index (Atkinson and Walton, 1967), could be used as a surrogate measure for flux in the 
thioredoxin system. This charge could be described in terms of either thioredoxin moiety, 
with the oxidative thioredoxin redox charge (TrxSS/Trx Total) or the reductive thioredoxin 
redox charge (TrxSH/Trx Total) measuring perturbations in oxidative demand and reductive 
supply respectively. Note that normalization against the total thioredoxin concentration 
ensures that the redox charge is bounded between zero and one allowing for comparative 
analyses between systems. In this chapter, computational modelling using a basic model of 
the E. coli thioredoxin system and comprehensive, in vivo computational models of hydrogen 
peroxide metabolism in the red blood cell (Benfeitas et al., 2014) and in the fission yeast, 
S. pombe (Tomalin et al., 2016) as well as in vitro assays were performed to test the utility of 
the thioredoxin redox charge as a surrogate measure for flux in the thioredoxin system under 
conditions of perturbed oxidative demand and reductive supply. 
 
4.2 Materials  
 The Thrombin CleanCleave™ Kit, Freund‟s complete and incomplete adjuvants were 
purchased from Capital Labs (Johannesburg, South Africa). The Pierce AminoLink
TM
 
coupling resin was obtained from Separations (Johannesburg, South Africa) while the Clarity 
western ECL substrate, nitrocellulose membrane, Precision Plus Protein™ WesternC™ 
standards and the Precision Protein™ StrepTactin-HRP Conjugate was obtained from Bio-
Rad, South Africa. The PageRuler
TM 
unstained protein ladder was purchased from Thermo 
Scientific (Johannesburg, South Africa). A HRP conjugated rabbit anti-chicken secondary 
antibody and all other common chemicals were from Merck/Saarchem (Johannesburg, South 
Africa) and were of the highest purity available.  
 
4.3 Methods 
4.3.1 Kinetic modeling 
Kinetic modeling experiments were carried out using the PySCeS modeling software 
(Olivier et al., 2005) (http://pysces.sourceforge.net) or the complex pathway simulator 
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(COPASI) software (http://copasi.org/). Simulations were carried out using a core model of 
the E. coli thioredoxin system (Pillay et al., 2011) and realistic models of the red blood cell 
(Benfeitas et al., 2014) and hydrogen peroxide-induced peroxiredoxin oxidation in S. pombe 
(Tomalin et al., 2016). The red blood cell and fission yeast COPASI models were generously 
supplied by Prof. Armindo Salvador (University of Coimbra) and Dr Elizabeth Veal 
(Newcastle University) respectively. The model files are all available in the appendix.  
 
 
4.3.2 Antibody preparation 
   4.3.2.1 Chicken immunization  
    Recombinant Trx protein (50 μg/ml, 1.5 ml) was added to an equal volume of 
Freund‟s complete adjuvant and triturated to form a stable water-in-oil emulsion which was 
used to immunize two chickens intramuscularly, sterilized with 70% (v/v) ethanol on either 
side of the breast bone followed by booster injections with Freund‟s incomplete adjuvant at 
weeks 2, 4 and 6. Eggs collected prior to immunization served as the pre-immune control, 
and those collected throughout the 16 week immunization schedule were stored at 4°C until 
the IgY isolation was performed. Ethics permission was obtained from the UKZN animal 
ethics committee (ethics number: 037/15/Animal) for all animal experiments described in the 
chapter. 
 
   4.3.2.2 IgY isolation 
    Chicken immunoglobulin (IgY) was isolated from the eggs collected at each 
week following the protocol of Goldring and Coetzer (2003). Briefly, the yolk was separated 
from the egg white and carefully rinsed under running water to remove all the albumin. The 
yolk sac was punctured and discarded and the yolk volume determined. Two volumes of 
100 mM phosphate buffer (pH 7.6) containing 0.02% (w/v) sodium azide were added to the 
yolk and mixed thoroughly using a glass rod. A sample was removed and 
PEG 6,000 (3.5% (w/v)) was added and stirred gently until the PEG completely dissolved. 
The solution was then centrifuged (4,420 x g, 20 min, room temperature) and the resulting 
supernatant was filtered through absorbent cotton wool which was placed at the base of a 
funnel. The filtrate volume was recorded and another sample (50 μl) was removed. 
PEG 6,000 was then added to the filtrate to a concentration of 12% (w/v) and stirred gently 
until completely dissolved. The resulting mixture was centrifuged (12,000 × g, 10 min, room 
temperature) and a further sample (50 μl) was taken from the supernatant. The remaining 
supernatant was discarded and the pellet was dissolved in a volume of phosphate buffer equal 
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to the original egg yolk volume. PEG 6,000 was added to a final concentration of 12% (w/v) 
and allowed to dissolve completely with gentle stirring. This mixture was then centrifuged 
(12,000 × g, 10 min, room temperature) and a sample (50 μl) was taken from the supernatant 
before discarding. The pellet was resuspended in ⅙ of the original egg yolk volume in 
100 mM phosphate buffer (pH 7.6) containing 0.1% NaN3 and a sample removed for SDS-
PAGE analysis (data not shown). The isolated IgY was then stored at 4 °C.  
 
   4.3.2.3 Preparation of AminoLink
TM
 matrix for antibody purification 
    Purified Trx was coupled to the AminoLink
TM
 coupling resin for the affinity 
purification of antibodies produced against this recombinant protein. The resin (1 ml) was 
equilibrated with 6 column volumes of coupling buffer (100 mM NaH2PO4, 0.05% (w/v) 
NaN3, pH 7.2) in a mini-column. Recombinant Trx (5 mg) dialysed against the coupling 
buffer was added to the resin with cyanoborohydride solution (40 μl 5M NaCNBH3 in 
1M NaOH) and mixed overnight at 4°C using a Revolver™ 360° Sample Mixer (Whitehead 
Scientific, Cape Town, South Africa). The unbound fraction was collected and the protein 
concentration was compared to fractions retained prior to coupling. The column was washed 
with coupling buffer (4 ml) and thereafter with an equal volume of quenching buffer 
(1 M Tris-HCl buffer, pH 7.4). Cyanoborohydride solution (40 μl) and quenching buffer 
(2 ml) were added to the resin and mixed using a Revolver™ 360° Sample Mixer (30 min at 
RT).  The column was then drained and washed with 1 M NaCl (10 ml) and 10 ml wash 
buffer (100mM NaH2PO4, 0.2% (w/v) NaN3, pH 6.5) and thereafter stored upright at 4 ºC 
until required. 
 
   4.3.2.4 Purification of polyclonal anti-Trx 1 antibodies 
    The AminoLink
TM
 affinity column was equilibrated with 6 column volumes of 
1 x PBS (137 mM NaCl, 3 mM KCl, 7 mM Na2HPO4 and 1.5 mM KH2PO4, pH 7.4) and the 
isolated IgY (4.3.2.2) was pooled, diluted with an equal volume of 1 x PBS and circulated 
over the column overnight at room temperature. The unbound IgY was collected and the resin 
was subsequently washed with 10 column volumes of 1 x PBS. The bound IgY, specific to 
the Trx on the column, was then eluted with a change in pH by adding elution buffer (8 ml, 
100 mM glycine-HCl, 0.02% (w/v) NaN3, pH 2.8) and 950 μl fractions were collected into 
microcentrifuge tubes containing 50 μl neutralisation buffer (1 M NaH2PO4, 
0.02% (w/v) NaN3, pH 8.5). The IgY concentration was then determined by measuring the 





= 1.25) (Goldring and Coetzer, 2003). The affinity purified IgY-containing fractions were 
pooled and NaN3 was added to a final concentration of 0.1% (w/v) before storing at 4°C. The 
affinity columns were washed with 12 column volumes of 1 x PBS buffer, equilibrated with 
12 column volumes of 1 x PBS buffer containing 0.05% NaN3 and thereafter stored at 4°C. 
 
4.3.3 Recombinant purification of TSA 
 A pET28a expression plasmid containing TSA1 was obtained from Miss B.D Eagling 
(Genetics, UKZN) and the identity of this clone was confirmed by DNA sequencing. TSA1 
expression was induced by using a high cell density culture method (Sivashanmugam et al., 
2009). Briefly, E. coli BL21 cells transformed with the TSA1 expression plasmid were grown 
at 37ºC (overnight, 150 rpm) in 2 x YT media (1.6% (w/v) tryptone, 1% (w/v) yeast extract, 
0.5% (w/v) NaCl, pH 7.0) containing kanamycin (30 µg/ml), centrifuged (1,500 x g, 10 min, 
RT) and resuspended in high cell density media (2 x YT, 50 mM Na2HPO4, 25 mM KH2PO4, 
5 mM MgSO4, 0.2 mM CaCl2, 0.1% (w/v) NH4Cl, 1% (v/v) glucose, pH 8.2). The cells were 
grown at 37ºC until the OD600 had increased by one unit (1-1.5 hours, 150 rpm). IPTG 
(0.5 mM) was then added to the cultures and induction of the recombinant protein expression 
proceeded at 30ºC (2 hours, 150 rpm). Cells were centrifuged at room temperature (12,000 
x g, 10 min) and the crude extract containing TSA1 was prepared as described previously 
(section 2.8.1). Thereafter recombinant TSA1 was purified using Ni-NTA affinity 
chromatography (section 2.8.2) while purified Trx and thioredoxin reductase were obtained 
as described previously (section 2.8).  
 
The activity of purified peroxiredoxin was determined using a DTT peroxidase assay in 
which DTT oxidation was monitored at 310 nm (Tairum et al., 2012) in the presence of 
hydrogen peroxide. The final reaction mixture contained 25 mM potassium phosphate 
(pH 7.0), 1 mM EDTA, 100 mM ammonium sulfate, 30 μM hydrogen peroxide, freshly 
prepared DTT (10 mM) and varying concentrations of TSA1 (1 μM, 2 μM) in a final volume 
of 1 ml.  The reaction was initiated by the addition of the TSA1 and proceeded at 30°C for 
10 min with the change in absorbance at 310 nm being directly monitored using a sample 
without TSA1 as the reference cuvette. Absorbance measurements were made with a UV-




4.3.4 His-tag cleavage of recombinant thioredoxin reductase and peroxiredoxin  
 The Thrombin CleanCleave™ Kit from Sigma was used for the cleavage of TRR1 and 
TSA1 His-tags. Both recombinant proteins were dialysed with 1 x cleavage buffer 
(50 mM Tris-HCl, 10 mM CaCl2, pH 8.0) to remove any residual salts present from the 
affinity purification process which could inhibit cleavage. Thrombin resin (100 μl) was 
centrifuged (500 x g, 3 min, RT) and the supernatant was discarded. The resin was twice 
washed with 1 x cleavage buffer (500 μl) and thereafter resuspended in 100 μl of 10 x 
cleavage buffer (500 mM Tris-HCl, 100 mM CaCl2, pH 8.0). Approximately 1 mg of 
recombinant protein was added to the mixture and made up to a final volume of 1 ml with 
distilled water. The reaction was incubated overnight at room temperature using the 
Revolver™ 360° Sample Mixer. The thrombin resin was removed from the sample (500 x g, 
3 min, RT) and the supernatant was treated with AEBSF (final concentration, 0.5 mM) to 
inhibit any further thrombin activity. Samples were pooled and incubated on a Ni-NTA 
column as described above (section 2.8.2) to separate the cleaved proteins from the uncleaved 
proteins which was confirmed by SDS-PAGE. The cleaved proteins, no longer containing the 
His-tag, eluted as the unbound fraction whilst the His-tagged proteins bound to the column. 
The thrombin resin was regenerated by washing with an equal volume of 50 mM Tris-HCl 
(pH 8.0) containing 500 mM NaCl and thereafter washing twice with an equal volume of 
50 mM Tris-HCl (pH 8.0). The regenerated resin was then resuspended in storage buffer 
(50% glycerol, 20 mM Tris-HCl, pH 8.0) and stored at 4°C. 
 
4.3.5 Kinetic assays  
 The concentration of freshly prepared NADPH was verified at A340 using the extinction 




. The initial assay contained 150 μM NADPH, 
1 μM thioredoxin, thioredoxin reductase (0-700 nM) and reaction buffer (25 mM potassium 
phosphate, 1 mM EDTA, 100 mM ammonium sulfate, pH 7.0) in a 1 ml UV cuvette which 
was equilibrated at 25°C for 15 minutes before the assay was initiated by the addition of 
peroxiredoxin. The consumption of NADPH was monitored as a decrease in absorbance at 
340 nm. Absorbance measurements were collected over 6 min and initial studies showed that 
the system remained in steady state beyond this period. A series of assays were performed 
with varying thioredoxin reductase (0-700 nM) and peroxiredoxin concentrations (0-4000 




 The steady state assay components were alkylated as described previously (Section 3.3.3) 
with minor modifications. Firstly, the TCA concentration was increased from 10% to a final 
concentration of 20% according to the manufacturer‟s instructions as higher TCA 
concentrations were recommended for proteins smaller than 20 kDa. Although no 
quantifiable differences in the protein yield were obtained between the two concentrations 
tested, a final concentration of 20% TCA was used for all the alkylation experiments 
described in this chapter. Additionally, the centrifugation of the TCA-treated samples in an 
Amicon® Ultra 2 ml centrifugal filter (10,000 NMWL) which was previously used to remove 
insulin (Section 3.3.3) was omitted in this experiment and the excess TCA was removed by 
an additional acetone (200 µl) wash step. The pellets were treated as described previously 
(Section 3.3.3) and the alkylated fractions were then separated by electrophoresis on a 
12.5% acrylamide SDS gel. All assays were undertaken in triplicate and as assay migration 
controls, reduced thioredoxin was obtained by incubating thioredoxin (1 µM) with 
thioredoxin reductase (0.1 µM), NADPH (150 μM) and reaction buffer at 25°C for 
15 minutes, while purified thioredoxin (1 μM) served as the oxidized control.  
 
4.3.6 Western blot  
 Upon completion of the SDS-PAGE, the gel was sandwiched between a nitrocellulose 
membrane (0.2 µm) and two stacks of filter paper that had been presoaked in transfer buffer for 
5 min to allow for the transfer of the proteins from the gel to membrane. Electrophoretic 
transfer was then carried out for 7 min at 25 V using the Trans-Blot
®
 Turbo™ transfer system 
(Bio-Rad). Total proteins on the membrane were detected with ponceau S staining while the 
gel was stained with Coomassie brilliant blue to confirm that complete transfer had occurred. 
All western blotting procedures were carried out at room temperature with agitation unless 
stated otherwise. The nitrocellulose membrane was blocked with 10% (w/v) BSA in TBST 
(20 mM Tris; 137 mM NaCl, 0.1% Tween-20, pH 7.6) for 30 min. Thereafter, the blocking 
buffer was removed and the blot was incubated overnight at 4°C with the chicken anti-
thioredoxin polyclonal primary antibody solution (1:3,000) prepared in 5% (w/v) BSA-TBST 
(Section 4.3.2.4). Removal of excess primary antibodies was carried out by washing the 
membrane in TBST six times for 2 min each. A HRP conjugated rabbit anti-chicken 
secondary antibody solution (1:3,000) prepared in 5% (w/v) BSA-TBST was then incubated 
with the membrane for 1 hour. The blot was washed again with TBST as described above and 
thereafter the membrane was incubated with the Clarity western ECL substrate for 3 min at room 





4.4.1 Comparative analysis of the thioredoxin redox charge and the existing in vivo 
measures of the Trx system. 
 Several measures have been used to quantitatively describe the activity of the Trx system 
in vitro and in vivo including specific activities, redox potentials (Watson et al., 2003) and 
redox ratios (Nkabyo et al., 2002, Trotter and Grant, 2003, Watson and Jones, 2003). To 
determine if any of these existing measures correlate with the flux through the system, a core 
model of the E. coli Trx system was analyzed (Pillay et al., 2011) which included reactions 
for the reduction of oxidized thioredoxin (TrxSS) by thioredoxin reductase, the thioredoxin-
dependent reductions of methionine sulfoxide (Met-S-SO) by methionine sulfoxide reductase 
(MsrA) and 3‟-phosphoadenosine-5‟-phosphosulfate (PAPS) by PAPS reductase (PR), the 
non-specific reduction of cytosolic protein disulfides (PSS) as well as the peroxiredoxin 
(Tpx)-dependent reduction of hydrogen peroxide (Figure 4.1, Table 4.1). As a control, the 
model was simulated and the model‟s steady-state behavior corresponded with published 
results (Pillay et al., 2011). Further and consistent with published results (Pillay et al., 2011), 
varying the concentrations of other oxidative demands such as PSS, PAPS and MetSO did 
not result in major flux changes (data not shown) and were therefore not analyzed further. 
  
 Simulations with varying concentrations of the reductive supplies, NADPH and 
thioredoxin reductase (TR) as well as the oxidative demands, hydrogen peroxide and 
peroxiredoxin (Tpx) were performed and the effect on flux, redox potentials, redox ratios 
(TrxSH/TrxSS), the oxidative thioredoxin redox charge (TrxSS/Trx Total) and the reductive 
thioredoxin redox charge (TrxSH/Trx Total) were determined. Although varying NADPH 
and TR or hydrogen peroxide and Tpx effectively represented a Trx supply or demand 
perturbation respectively (Figure 4.1), each parameter was tested to account for any 







Table 4.1 Kinetic parameters and species concentrations used in the core model of the 
E. coli thioredoxin system (Adapted from Pillay et al., 2011) 
Reaction Parameter Value 
NADPH + TrxSS   NADP + TrxSH kcat1 22.75 s
-1
 
 Knadph 1.2 μM 
 K1trxss 2.8 μM 
 Thioredoxin reductase 4.74 μM 





MetSO + TrxSH  Met + TrxSS kcat3 3.7 s
-1
 
 Kmetso 1900.0 μM 
 K3trxsh 10.0 μM 
 Methionine sulfoxide reductase 2.35 μM 
PAPS + TrxSH  SO3 + PAP + TrxSS kcat4 3.5 s
-1
 
 Kpaps 22.5 μM 
 K4trxsh 13.7 μM 
 PAPS reductase 0.345 μM 










Species Concentration (µM)  
NADPH 137.0  
NADP 1.0  
TrxSH 1.0  
TrxSS 1.0  
PSS 4.23  
PSH 1.0  
MetSO 970.0  
Met 4.83 × 10
4
  
PAPS 0.07  
PAP 1.0  
SO3 1.0  
H2O2 0.02  
H2O 1.0  
TpxSH 4.88  






 As the system‟s flux was perturbed by varying the NADPH or thioredoxin reductase 
concentration, the redox potential (Figure 4.2 A and E), redox ratio (Figure 4.2 B and F) as 
well as the oxidative thioredoxin redox charge (Figure 4.2 C and G) showed poor correlations 
with the flux. However, as these perturbations would be expected to distribute the thioredoxin 
redox couple into its reduced moiety, the reductive thioredoxin redox charge correspondingly 
appeared to follow changes in the flux (Figure 4.2 D and H).  
 
 
Figure 4.2 The reductive thioredoxin redox charge correlated with the flux as the 
reductive supply from NADPH and thioredoxin reductase increased. Varying 
concentrations of NADPH and thioredoxin reductase (TR) were used to determine the 
relationship between the flux (blue) and redox potential (cyan, A and E), redox ratio 
(TrxSH/TrxSS) (green, B and F), oxidative thioredoxin redox charge (TrxSS/Trx Total)  (red, 
C and G) and reductive thioredoxin redox charge (TrxSH/Trx Total) (magenta, D and H).  
 
 To simulate oxidative demand conditions, the hydrogen peroxide and Tpx concentrations 
were increased (Figure 4.3) which would be expected to trigger the oxidation of the 
thioredoxin redox couple. Under these conditions, the redox ratio which has commonly been 
used to measure the thioredoxin system (Nkabyo et al., 2002, Trotter and Grant, 2003, 
Watson and Jones, 2003) and the reductive redox charge did not correlate with the flux 
(Figure 4.3 B, F, D, H) while the oxidative thioredoxin redox charge most closely tracked 





Figure 4.3 The oxidative thioredoxin redox charge corresponded with the flux as the 
oxidative demand increased. The relationship between the flux (blue) and existing measures 
of the thioredoxin system including the redox potential (cyan, A and E), redox ratio 
(TrxSH/TrxSS) (green, B and F), oxidative thioredoxin redox charge (TrxSS/Trx Total) (red, 
C and G) and reductive thioredoxin redox charge (TrxSH/Trx Total) (magenta, D and H) 
were evaluated with varying concentrations of H2O2 and Tpx, respectively. 
 
 The redox potential which has been used as an endpoint quantitative measure in several 
studies (Jones, 2006, Kranner et al., 2006) showed a surprising correlation to oxidatively-
induced changes in the flux (Figure 4.3 A and E). A number of studies have highlighted the 
limitations associated with this measure (Flohé, 2010, Pillay et al., 2013) and it was therefore 
hypothesised that the log function within the Nernst equation (Chapter 1) was normalising the 
thioredoxin redox ratio (Feng et al., 2014). To test this hypothesis, the flux, redox ratio and 
the log transformed redox ratio data were plotted simultaneously with NADPH and hydrogen 
peroxide perturbations. Rather than revealing a true correlation with electrochemical 
potential, logarithmic transformation of the thioredoxin redox ratio data was indeed 






Figure 4.4 The flux through the thioredoxin system correlated with the log 
transformation of the thioredoxin redox ratio.  Models with varying concentrations of 
NADPH (A-B) and H2O2 (C-D) were simulated and the effect on the flux (blue) and the 
thioredoxin redox ratio, (TrxSH/TrxSS) (A and C, green) or (TrxSS/TrxSH) (B and D, green) 
was investigated. The log transformation of the respective redox ratio (red) was 
simultaneously plotted. 
 
 Once a qualitative relationship between each of the measures of the thioredoxin system 
and the flux was established, co-response plots were generated to determine the quantitative 
relationship with varying concentrations of hydrogen peroxide, peroxiredoxin, NADPH and 
thioredoxin reductase (Figure 4.5). Co-response plots allow for quantitative analysis of how 
perturbations of supply and demand determine the behaviour and control of the flux of a 
system (Hofmeyr and Cornish-Bowden, 2000). The plots were generated in double log-space 
as the use of logarithmic rather than linear scales offers several advantages; the most 
important being that it allows direct comparison of the magnitude of steady-state responses to 
perturbations even with different fluxes and concentrations (Hofmeyr, 1995). 
 
As the reductive supply from NADPH and thioredoxin reductase increased, the oxidative 
redox charge (Figure 4.5 C) showed no correlation with the flux while the redox potential 
(Figure 4.5 A), the redox ratio (Figure 4.5 B) and the reductive thioredoxin redox charge 
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(Figure 4.5 D) appeared to correspond with the flux within limits. Notably at very high 
reductive supply conditions, the relationship between the reductive thioredoxin redox charge 
and the flux was non-linear (Figure 4.5 D) which reflected a limitation in this computational 
model. As the reductive supply was increased, the Tpx redox cycle became saturated and 
therefore further increases in the reduced thioredoxin concentration did not result in 
corresponding changes to the flux. Increasing the concentration of hydrogen peroxide would 
therefore result in an increased demand for reduced Tpx and a linear relationship between the 
reductive thioredoxin redox charge and the flux was subsequently obtained (Figure S1). The 
co-response plots also revealed that with perturbations in both oxidative demands, the 
oxidative thioredoxin redox charge showed a quasi-linear relationship to the flux over a 
1000-fold change in the flux (Figure 4.5 G) while the other measures showed a non-linear 
response. In these simulations, the reductive supply was not limiting and therefore the redox 
charge tracked the flux over a large range. Collectively these results strongly argued that the 
thioredoxin reductive and oxidative redox charges may be surrogate measures for flux within 





Figure 4.5 Co-response analysis confirms that the reductive and oxidative thioredoxin 
redox charge correlated with the flux under reductive supply and oxidative demand 
conditions, respectively. Co-response plots were generated for NADPH (-) and thioredoxin 
reductase (.-.) (A-D) as well as H2O2 (-) and peroxiredoxin (.-.) (E-H) perturbations and the 
relationship with the redox potential (A and E), redox ratio (TrxSH/TrxSS) (B and F), 
oxidative thioredoxin redox charge (TrxSS/Trx Total) (C and G) and reductive thioredoxin 
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redox charge (TrxSH/Trx Total) (D and H) was determined. Each y-axis was scaled 
according to the range of output values for each measure.  
 
The applicability of the surrogate measure in drug design studies was also tested as the Trx 
system represents an attractive target for drug therapy (Welsh et al., 2003, Jones et al., 2006, 
Urig and Becker, 2006, Cai et al., 2012, Fan et al., 2014, Saccoccia et al., 2014, Ahrens et 
al., 2015). As a first step, Ebselen, a competitive inhibitor which reacts with the active site 
dithiol of the E. coli thioredoxin reductase enzyme (Lu et al., 2013), was incorporated into 
the E. coli thioredoxin system core model. The effect of varying concentrations of the 
inhibitor on each of the thioredoxin measures was then tested. As Ebselen inhibits the activity 
of thioredoxin reductase, it was expected that increasing inhibitor concentrations would 
decrease both the flux through the system as well as the concentration of reduced thioredoxin 
available. The computational modeling results supported these expectations (Figure 4.6) and 
corroborated published in vitro data where the fast oxidation of thioredoxin by ebselen was 
shown through alkylation and western blotting analysis (Lu et al., 2013). In addition 
treatment of a cell with thioredoxin reductase specific inhibitors also causes a decrease in the 
amount of reduced Trx present (Lu et al., 2006, Du et al., 2012). 
 
The modeling results revealed that the redox potential (Figure 4.6 A), redox ratio 
(Figure 4.6 B) and the oxidative thioredoxin redox charge (Figure 4.6 C) showed a weak or 
no correlation with the flux. Not surprisingly, the reductive thioredoxin redox charge 
corresponded with the flux with increasing inhibitor concentrations (0-5 µM) as this inhibitor 
affects the reductive supply of the system (Figure 4.6 D). The thioredoxin redox charge could 
therefore serve as a useful measure for analyzing therapeutics that target the reductive 
thioredoxin supply in vivo. 
 
As the S. cerevisiae clones for thioredoxin reductase, Trx (Chapter 3) and peroxiredoxin 
were readily available, these computational modeling results were tested using in vitro kinetic 




Figure 4.6 The reductive thioredoxin redox charge correlated with the flux with varying 
concentrations of a competitive inhibitor. Simulations were performed with varying 
concentrations of Ebselen and the relationship between the flux (blue) and redox potential 
(cyan, A), redox ratio (TrxSH/TrxSS) (green, B), oxidative thioredoxin redox charge 
(TrxSS/Trx Total) (red, C) and reductive thioredoxin redox charge (TrxSH/Trx Total) 
(magenta, D) was tested. The effect of the inhibitor on the concentration of reduced 
thioredoxin (black, A-D) was also determined. It should be noted that the reductive 
thioredoxin redox charge plot was superimposed on the reduced thioredoxin plot (D). 
 
4.4.2 The thioredoxin redox charge tracks changes in the thioredoxin reductive 
supply and oxidative demand in vitro 
To perform the in vitro analysis, recombinant thioredoxin reductase, Trx (Chapter 3) and 
the yeast peroxiredoxin, TSA1 had to be expressed and purified using nickel affinity 
chromatography. TSA1 was successfully purified with a size of 24 kDa (Figure 4.7) which 
was close to the expected size of 22 kDa and its activity was confirmed using a DTT 
peroxidase assay in which the oxidation of DTT was monitored at 310 nm (Tairum et al., 






Figure 4.7 Ni-NTA affinity purification of recombinant TSA1. TSA1 expression was 
induced for 2 hours and the cells processed as described in Section 2.8.1 to yield pure TSA1. 
The gel was stained with Coomassie blue. 
 
Previous studies found that the presence of C-terminus His-tags on peroxiredoxins could 
negatively affect protein activity due to a change in its native structure (Cao et al., 2007, 
Barranco-Medina et al., 2009). The conformation of the N-terminus tagged TSA1 used in this 
study was determined by a Blue Native (BN)-PAGE which uses Coomassie blue dye to 
resolve proteins by supplying a charge to allow them to separate according to size in their 
native form and omits detergents such as SDS that disrupt protein-protein interactions in 
typical protein electrophoresis (Manns, 2005). The BN-PAGE of TSA1 revealed that this 
protein assembled into a high molecular weight decameric structure and the presence or 
absence of the His-tag did not affect its activity (Eagling, 2015). However, both 
peroxiredoxin and thioredoxin reductase were recognised by the polyclonal antibodies 
produced for Trx because the His-tag epitope was present on both proteins. These tags were 
therefore cleaved and the cleaved proteins were purified using nickel affinity chromatography 
(Figure 4.8 A).  
 
To confirm if the His-tag cleavage was successful as well as to test the specificity of the 
antibodies generated against Trx1, a western blot was performed using polyclonal anti-
thioredoxin antibodies. Purified thioredoxin which served as the oxidized Trx control 
(Ox Trx1) in the alkylation studies was also analyzed.  
       Crude       Un-            Wash eluates       Pure TSA1 








Nickel affinity purification depends on the binding of the histidine residues in the His-tag 
of the recombinant protein to the immobilized nickel ions in the resin. Upon cleavage of the 
His-tag, the proteins elute from the resin as the unbound fraction providing an efficient 
method to separate the cleaved proteins from the uncleaved fractions. The His-tag is 
approximately 1 kDa in size and therefore cleavage causes a subsequent decrease in the 
molecular weight of the recombinant protein (Figure 4.8 A). Cleavage of the His-tags from 
recombinant TRR1 and TSA1 prevented cross-detection by the anti-Trx 1 antibodies 
(Figure 4.8 B) and the western blot confirmed that the antibodies were able to detect the 




Figure 4.8 Nickel affinity purification of His-tag cleaved recombinant TSA1 and 
TRR1 (A) and western blot analysis confirming the specificity of the anti-Trx1 
antibodies (B and C). His-tags from TSA1 and TRR1 were cleaved using the Thrombin 
CleanCleave kit and the extract was mixed with Ni-NTA agarose. The proteins cleaved to 
completion eluted as the unbound fractions and ran at a lower molecular weight when 
analyzed by SDS-PAGE. The gel in this figure was stained with Coomassie blue (A). 
Western blotting analysis confirmed that the cleavage removed the His-tag (B) and the 
polyclonal antibodies specifically recognised thioredoxin (Ox Trx1) (C). The gels have been 





 Using the His-tag cleaved proteins and Trx, kinetic analysis involving the 
spectrophotometric monitoring of the flux as the rate of NADPH oxidation with varying 
thioredoxin reductase (reductive supply) or peroxiredoxin concentrations (oxidative demand) 
was performed to determine if the thioredoxin redox charge is a surrogate measure for flux in 
vitro. With increasing thioredoxin reductase and TSA concentrations, a corresponding 
increase in the flux was observed (Figure 4.9). In keeping with computational modeling 
studies (Pillay et al., 2011, Rohwer et al., 2016), the flux displayed an ultrasensitive response 
to perturbations of the reductive supply and the oxidative demand showing how the flux was 
a function of the activity of demand and supply reactions respectively (cf. Figure 4.5). To the 










Figure 4.9 The rate of NADPH oxidation was measured at 340 nm at various 
concentrations of thioredoxin reductase (0-700 nM) (A) and peroxiredoxin (0-4000 nM) 










































































reaction buffer (25 mM potassium phosphate, 1 mM EDTA, 100 mM ammonium sulfate, 
pH 7.0), 100 nM TRR1 for varying TSA1 assays (A) and 250 nM TSA1 for varying TRR1 
assays (B). Experiments were performed in triplicate and the standard error bars are 
indicated.  
 
Based on previous data (Chapter 3), it was expected that a reduced/alkylated thioredoxin 
isoform and lower molecular weight oxidized thioredoxin isoform would be obtained in these 
experiments. However, in migration control experiments where purified thioredoxin served as 
an oxidized thioredoxin control (Ox Trx), PEG-maleimide surprisingly appeared to increase 
the size of this thioredoxin isoform to 26 kDa without prior reduction in the assay 
(Figure 4.10 A) while a small fraction of the oxidized thioredoxin control remained at 15 kDa 
which was close to the expected size of 12 kDa. As an assay control to ensure that a 
functioning system was utilized in the assays, thioredoxin (1 µM) was reduced with NADPH 
(150 µM) and thioredoxin reductase (0.1 µM) which resulted in a higher molecular weight 
band (47 kDa) (Figure 4.10 A) corresponding to the alkylation of fully reduced thioredoxin 
(Chapter 3, Figure 3.4). DTT treatment of the oxidized thioredoxin control prior to alkylation 
resulted in the near-complete disappearance of the 15 and 26 kDa bands and the appearance 
of fully reduced thioredoxin at 47 kDa (Figure 4.10 B).  
 
Upon alkylation, PEG-maleimide binds to free thiols in proteins, increasing the molecular 
mass of the protein by 5 kDa per PEG-maleimide bound. Therefore, a fully oxidized form of 
thioredoxin should be approximately 12 kDa, a partially oxidized form should be 
approximately 17 kDa and a fully reduced and alkylated thioredoxin should have a size of 
22 kDa. However several studies have found that due to the extensive hydration of PEG, the 
mobility shift in SDS-PAGE can be much larger than expected, up to 22 kDa per PEG-
maleimide bound (Makmura et al., 2001, Chibani et al., 2011, Biran et al., 2014, Nikkanen et 
al., 2016) which was consistent with our findings. Three thioredoxin isoforms have 
previously been reported in alkylation studies which include the fully oxidized, partially 
oxidized and fully reduced forms (Requejo et al., 2010) and two oxidized forms of 
thioredoxin were also obtained in Candida albicans alkylation studies. Consistent with our 
results, both these forms were lost upon DTT treatment prior to alkylation with 4-acetamido-
4'-maleimidyl-stilbene-2,2'-disulfonate (AMS) confirming that the bands represented 
different oxidized forms of thioredoxin (da Silva Dantas et al., 2010). Thus, in our assays the 
two bands at 15 and 26 kDa following PEG-maleimide alkylation were assigned as the 
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oxidized thioredoxin fraction for this analysis, while the 47 kDa band represented the reduced 
thioredoxin fraction. It should be noted that the samples were not pre-reduced with DTT in 
these kinetic assays as this would have changed the reductive supply conditions in the assay.  
 
 The western blot analysis revealed that an increase in the thioredoxin reductase 
concentration resulted in a progressive increase in the concentration of the reduced Trx 
fraction relative to the oxidized fraction (Figure 4.10 C) while increases in peroxiredoxin 
concentration were accompanied by the conversion of the Trx moiety into its oxidized form 
(Figure 4.10 D). The intensity ratio of the bands from these western blots obtained with 
ImageJ (http://imagej.nih.gov/ij/) was combined with the in vitro assay data (Figure 4.9) to 
determine the correlation between each of the measures of the Trx system and the flux 
(Figure 4.11) as well as to generate co-response plots (Figure 4.12) to determine their 
quantitative relationships. At higher concentrations of the reductive supply or the oxidative 
demand, the demand or supply cycle saturated and therefore the measures of the Trx system 
were calculated across the entire dataset (Figure S2-S3) as well as within the initial linear 
regions. 
 
As the reductive supply from NADPH and thioredoxin reductase increased, the redox 
potential (Figure 4.11 A) most closely correlated with the flux. The redox ratio 
(Figure 4.11 B) and the reductive thioredoxin redox charge (Figure 4.11 D) showed a good 
correlation while the oxidative redox charge (Figure 4.11 C) showed no correlation with the 
flux. On the other hand, with increasing concentrations of peroxiredoxin, the oxidative redox 
charge (Figure 4.11 G) most closely correlated with the flux compared to all the measures 
tested. The co-response analysis revealed non-linear plots for the correlation between the flux 
and the redox potential (Figure 4.12 A) as well as the oxidative thioredoxin redox charge 
(Figure 4.12 C) with increasing concentrations of thioredoxin reductase. Consistent with the 
modeling results obtained above (Figure 4.5), both the redox ratio (Figure 4.12 B) and the 
reductive thioredoxin redox charge (Figure 4.12 D) correlated with the flux producing quasi-
linear plots. Both the redox potential (Figure 4.12 E) and the oxidative thioredoxin redox 
charge (Figure 4.12 G) displayed good correlations with the flux with perturbations in the 
peroxiredoxin concentration, while the redox ratio (Figure 4.12 F) and the reductive 
thioredoxin redox charge (Figure 4.12 H) showed no correlation. In summary, the in vitro 
analyses showed that the thioredoxin redox charge could be used as a surrogate measure for 
flux. As an additional study to test the applicability of thioredoxin redox charge as a surrogate 
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Figure 4.10 The effect of perturbations of the reductive supply and oxidative demand on 
the thioredoxin redox poise. For the alkylation studies, purified thioredoxin was used as an 
oxidative control (Ox Trx) and PEG-maleimide treatment increased the molecular weight of 
this control. In an assay control to ensure the reduction of Trx by thioredoxin reductase, 
incubation of thioredoxin (1 µM) with thioredoxin reductase (0.1 µM) and 
NADPH (150 µM) resulted in the appearance of reduced thioredoxin at 47 kDa (A) which 
was confirmed by DTT-pretreatment of oxidized thioredoxin (B). The kinetic assay samples 
containing NADPH (150 µM), thioredoxin (1 µM) and varying concentrations of thioredoxin 
reductase (TRR1) (C) or TSA1 (D) were alkylated with PEG-maleimide and the reduced 
thioredoxin concentration was detected using polyclonal chicken anti-thioredoxin antibodies. 
All bands were quantified with Image J. A reduced Trx fraction could not be detected in the 
1 nM TRR1 experiment (C) and therefore this fraction was assigned a nominal value of 0.1%. 
The gels have been cropped to fit the figures into this thesis but no other bands were observed 




Figure 4.11 The reductive thioredoxin redox charge correlated with the flux as the 
reductive supply from thioredoxin reductase increased while the oxidative thioredoxin 
redox charge correlated with the flux with increasing peroxiredoxin concentrations. In 
vitro assays with varying concentrations of thioredoxin reductase and peroxiredoxin were 
performed to determine the relationship between the flux (blue) and redox potential (cyan, A 
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and E), redox ratio (TrxSH/TrxSS) (green, B and F), oxidative thioredoxin redox charge 
(TrxSS/Trx Total)  (red, C and G) and reductive thioredoxin redox charge (TrxSH/Trx Total) 




Figure 4.12 Co-response plots generated from in vitro assay and western blot data 
confirmed that the reductive thioredoxin redox charge correlated with the flux with 
perturbations in reductive supply and the oxidative thioredoxin redox charge correlated 
with the flux with perturbations in oxidative demand. Co-response plots were generated 
with varying concentrations of thioredoxin reductase (A-D) and peroxiredoxin (E-H) and the 
relationship with the redox potential (A and E), redox ratio (TrxSH/TrxSS) (B and F), 
oxidative thioredoxin redox charge (TrxSS/Trx Total) (C and G) and reductive thioredoxin 
redox charge (TrxSH/Trx Total) (D and H) was determined. 
 
4.4.3 Realistic models illustrated the general applicability of the thioredoxin redox 
charge as a surrogate measure for flux 
 A published model of the red blood cell was used to test the general applicability of the 
proposed surrogate measure. This comprehensive model was based on hydrogen peroxide 
metabolism in erythrocytes and included reactions for the (i) generation of intracellular 
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hydrogen peroxide from both endogenous and exogenous sources; (ii) hydrogen peroxide 
consumption via catalase, peroxiredoxin 2 and glutathione peroxidase; (iii) peroxiredoxin 2 
sulfinylation and reduction of the sulfinic to the sulfenic form; (iv) Trx1 oxidation by 
peroxiredoxin 2, reduction via thioredoxin reductase and reactions between the active-site 
dithiol and the regulatory dithiol; (v) glutathione reductase mediated reduction of glutathione 
disulfide (GSSG); and (vi) NADP
+
 reduction to NADPH by the hexose monophosphate shunt 
(Benfeitas et al., 2014). A diagrammatic representation of the model (Figure S4) as well as 
tabulated kinetic parameters and species concentrations are given in the appendix (Table S2). 
  
 The model was simulated with increasing hydrogen peroxide concentrations, the effect on 
each of the measures of the Trx system was determined (Figure 4.13 A-D) and thereafter co-
response plots were generated (Figure 4.13 E-H). As the concentration of hydrogen peroxide 
increased, the redox potential (Figure 4.13 A), redox ratio (Figure 4.13 B) and reductive 
thioredoxin redox charge (Figure 4.13 D) showed no correlation with the flux. However, this 
perturbation resulted in an increased demand for peroxiredoxin reduction, leading to greater 
oxidized thioredoxin concentrations at steady state and the oxidative thioredoxin redox 
charge consequently correlated with the flux (Figure 4.13 C). The co-response plots 
confirmed this finding and a linear relationship between the flux and the oxidative 
thioredoxin redox charge (Figure 4.13 G) was obtained. 
 
An additional realistic computational model monitoring hydrogen peroxide-induced 
peroxiredoxin oxidation in S. pombe was also analyzed to investigate the applicability of the 
thioredoxin redox charge as a surrogate measure of flux. This model was able to accurately 
simulate the in vivo removal of extracellular hydrogen peroxide and also included the 
changes in the concentrations of the various peroxiredoxin redox states following exposure to 
different hydrogen peroxide concentrations. The rates of hydrogen peroxide influx and efflux 
as well as the removal of hydrogen peroxide from the intracellular compartment were also 
included in the model. Notably, this model displayed excellent predictive abilities and 
provided new insights into the underlying causes and function of peroxiredoxin 
hyperoxidation (Tomalin et al., 2016). A diagrammatic representation of the model 
(Figure S5) as well as tabulated kinetic parameters and species concentrations are given in the 





Figure 4.13 A large scale realistic model of the red blood cell supports the use of the 
thioredoxin redox charge as a surrogate measure for flux. Plots with the flux (blue) and 
redox potential (cyan, A), redox ratio (TrxSH/TrxSS) (green, B), oxidative thioredoxin redox 
charge (TrxSS/Trx Total) (red, C) and reductive thioredoxin redox charge (TrxSH/Trx Total) 
(magenta, D) were generated with varying concentrations of hydrogen peroxide. Using this 
respective data, co-response plots were then generated (E-H). 
  
 The model was simulated with increasing hydrogen peroxide concentrations and the effect 
on each of the measures of the Trx system including the redox potential, the redox ratio, the 
oxidative thioredoxin redox charge and the reductive thioredoxin redox charge was 
determined (Figure 4.14 A-D) and co-response plots were also generated (Figure 4.14 E-H). 
Of all the measures tested, the oxidative thioredoxin redox charge most closely correlated to 
the flux (Figure 4.14 C) with perturbations in hydrogen peroxide concentration. A linear 
curve was also obtained during the co-response analysis confirming a corresponding 
quantitative relationship between the flux and the oxidative thioredoxin redox charge 





Figure 4.14 A realistic model of the in vivo oxidation of S. pombe peroxiredoxin 
supported the use of the thioredoxin redox charge as a surrogate measure for flux. Plots 
with the flux (blue) and redox potential (cyan, A), redox ratio (TrxSH/TrxSS) (green, B), 
oxidative thioredoxin redox charge (TrxSS/Trx Total) (red, C) and reductive thioredoxin 
redox charge (TrxSH/Trx Total) (magenta, D) were generated with varying concentrations of 
H2O2. Co-response plots were then generated (E-H) using this respective data. 
 
4.5 Discussion 
Several measures including Trx and thioredoxin reductase specific activities (Lovell et al., 
2000) cellular Trx redox potentials (Watson et al., 2003) and redox ratios (Nkabyo et al., 
2002, Trotter and Grant, 2003, Watson and Jones, 2003) have all been used to describe the 
thioredoxin system in vitro and in vivo. Although these measures are informative, the 
connectivity, interactions and ultimately the complexity of the Trx network deem the 
measurement of individual constituents within the network insufficient as they cannot 
describe the emergent behaviour of the integrated system. A system measure such as flux 
could provide a comprehensive and integrated measure of the reductive supply and oxidative 
demand activities on the system.  
 
Currently, in vitro assays determine the flux by monitoring the rate of NADPH oxidation 
(Chapter 3) but this approach is not practical in vivo which prompted a search for a surrogate 
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measure for flux. In addition to the existing measures of the Trx system, a novel measure, the 
thioredoxin redox charge analogous to the energy charge index (equation 4.1) was tested as a 
surrogate measure for flux. 
 
𝐸            =
         
[   ] [   ] [   ]
                             (4.1) 
 
where ATP represents adenosine triphosphate, ADP is adenosine diphosphate and AMP is 
adenosine monophosphate, also known as 5'-adenylic acid.  
  
 The energy charge provides a quantitative measure for the energetic state of a biological 
system (Atkinson and Walton, 1967) and depends on the individual concentrations of ATP, 
ADP and AMP. This index can have a value ranging from from 0 if only AMP is present to 1 
if all the AMP is converted to ATP and is mechanistically based on the adenylate kinase 
equilibrium (Metzler and Metzler, 2001). Similarly, the thioredoxin redox charge, based on 
the mechanism of saturation in the Trx system, represents a quantitative measure for the flux 
and can also have a value ranging between 0 and 1. 
 
A core model of the E. coli Trx system (Pillay et al., 2011) was analyzed to determine 
how each of the measures of the Trx system corresponded to the flux under varying reductive 
supplies (thioredoxin reductase or NADPH) and oxidative demands (peroxiredoxin or 
hydrogen peroxide) (Figure 4.2-4.3) and revealed that the reductive thioredoxin charge and 
the oxidative thioredoxin charge corresponded to the flux under these conditions, 
respectively. A surprising correlation between the redox potential and the flux was also 
observed. Several studies have questioned the relevance of this measure as it only describes 
the electrochemical potential of a given reaction but not whether that reaction is kinetically 
relevant (Flohé, 2010, Flohé, 2013, Pillay et al., 2013). The modeling results showed that this 
unexpected correlation was due to the logarithmic transformation of redox ratio dataset 
(Figure 4.4).  
 
To determine the quantitative relationship between each of the measures and the flux 
through the system, co-response plots were generated (Figure 4.5) which revealed a quasi-
linear relationship between the oxidative thioredoxin charge and the flux when the system 
was experiencing oxidative demand. As the system‟s flux was perturbed by varying the 
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NADPH or thioredoxin reductase concentration, the reductive thioredoxin redox charge 
corresponded to the flux within limits determined by the complete saturation of the Tpx redox 
cycle. However for most applications, this limit would not be breached for an extended 
period as it is a consequence of a very high hydrogen peroxide load which would result in 
cell death. Promisingly, the reductive thioredoxin redox charge could be highly applicable in 
thioredoxin reductase inhibition studies as it showed a quasi-linear correlation to the flux 
under conditions that limited the Trx supply (Figure 4.6).  
 
As these modeling results could be tested in vitro, oxidative demand and reductive supply 
assays as well as western blot analysis using Trx specific antibodies (Figure 4.8) were 
performed and the utility of the thioredoxin redox charge as a surrogate measure for flux was 
shown (Figure 4.9-4.12). Further, comprehensive realistic models of the red blood cell 
(Benfeitas et al., 2014) and S. pombe (Tomalin et al., 2016) were also simulated with 
increasing concentrations of hydrogen peroxide (Figure 4.13-4.14) which confirmed the 
general applicability of the thioredoxin redox charge as a surrogate measure of flux.   
 
However, three limitations with the thioredoxin redox charge have been identified by this 
analysis. First, using this measure, concurrent perturbations in both the supply and demand 
cannot be individually tracked as the oxidative thioredoxin redox charge or the reductive 
thioredoxin charge measures the net overall change in the Trx system. The thioredoxin redox 
charge can only give a global measure of changes to flux in the Trx system. Second, at the 
upper limits of the reductive supply or the oxidative demand, the demand or supply cycle 
respectively can become saturated resulting in changes to the thioredoxin redox charge with 
no corresponding changes to the flux. However, it is unlikely that the in vivo reductive supply 
would be increased for an extended period as the flux through the pentose phosphate pathway 
can be dissipated to other reactions to reduce NADPH production. On the other hand, very 
high oxidative demands cause peroxiredoxin inactivation by hyperoxidation in eukaryotes 
(Poole and Nelson, 2008, Day et al., 2012, Collins et al., 2016) which preserves the Trx 
redox poise (Day et al., 2012). Thus, in these cells, the oxidative thioredoxin redox charge 
can still follow changes in the flux even under oxidative stress conditions which was shown 
in our modeling results (Figure 4.13-4.14). Third, while the thioredoxin charge cannot give a 
quantitative value to the thioredoxin system flux in vivo, it can be used to track changes in 




This work has a number of major applications in the field of redox biology. An advantage 
of the thioredoxin redox charge, compared to the redox potential and the redox ratio is that 
the normalization against the total thioredoxin concentration ensures that the redox charge is 
bounded between zero and one allowing for comparative analyses between systems. This 
measure therefore provides quantitative information that is directly comparable across 
laboratories. Further, from a technical standpoint this normalization approach also reduces „in 
gel‟ variability as the measure is normalized against the concentration of protein loaded in 
each lane. In addition, as the thioredoxin redox charge represents a system measure, a similar 
approach could be adopted for the analysis and quantification of other redoxin systems in 
vivo allowing for the role of redoxin networks in pathologies to be quantified. Notably as the 
thioredoxin redox charge follows changes in the flux through the system, it can be used as an 
independent method to confirm and validate perturbations in flux obtained through 
computational model data-fitting experiments. Finally, as this measure represents a surrogate 
measure for flux, it may be very useful for clinical/therapeutic studies of the Trx system 
which currently measure a large number of disparate parameters in order to obtain 
information on the system as a whole (Du et al., 2012, Lu et al., 2013, Jortzik et al., 2014, 
Raninga et al., 2015, Metcalfe et al., 2016). 
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Chapter 5: Conclusion 
  
“When you can measure what you are speaking about, and express it in numbers, you know 
something about it” -Lord Kelvin 
 
5.1 General discussion 
 The Trx system is the primary electron donor to several biosynthetic enzymes including 
ribonucleotide reductase, methionine sulfoxide reductase, and sulfate reductases, and reduces 
inter- and intramolecular disulfide bonds in oxidized proteins. It also serves a critical function 
in oxidative stress response in many organisms (Lu and Holmgren, 2014) by reducing 
deleterious disulfide bonds in oxidatively-damaged proteins and by reducing hydrogen 
peroxide scavengers such as peroxiredoxins. This system also regulates gene expression and 
cell signalling in bacteria, plants and mammals (Arnér and Holmgren, 2000b) and plays a role 
in the  pathology of HIV and Mycobacterium tuberculosis (Akif et al., 2008, Stantchev et al., 
2012, Lin et al., 2016).  
 
 Given the ubiquitous distribution and importance of Trx, the properties and functions of 
the system have been intensely investigated using molecular cell biology tools such as gene 
knockouts, proteomics, redox probes as well as enzyme kinetic approaches (Chapter 1). 
Although these methods have provided several insights into the biochemical properties and 
cellular functions of Trx, these methods have been limited at elucidating the emergent or 
system-dependant properties of the Trx system, and its multiple interactions with several 
cellular processes (Chapter 1). These limitations stimulated the development of 
computational modeling as a powerful complementary tool to conventional molecular 
biology and kinetic studies and several models of the Trx system and related redoxin systems 
have been developed, providing insights into key processes such as hydrogen peroxide 





Figure 5.1 A timeline of the computational models of redoxin systems. Several 
computational models have been developed to elucidate the behavior of redoxin networks in 
Jurkat T-cells (Adimora et al., 2010), the red blood cell (Benfeitas et al., 2014), HeLa (Lim et 
al., 2015) and lens epithelial cells (Dwivedi and Kemp, 2012) as well as E. coli (Pillay et al., 
2011), Trypanosoma cruzi (Olin-Sandoval et al., 2012), Candida albicans (Komalapriya et 
al., 2015) and S. pombe (Tomalin et al., 2016). 
 
In general, computational modeling is used for hypothesis and behavioural testing, 
generating new insights, and inspiring new approaches (Brodland, 2015). Modeling also 
permits tasks that are not experimentally feasible. For example, unlike physical experiments, 
computational modeling allows for an arbitrary number of experiments to be run from 
identical starting configurations and also allows for manipulations of arbitrary or user-defined 
magnitudes which might not be possible in conventional experimental systems. Further, 
modeling of in vivo systems can eliminate cell to cell variation if desired and more 
importantly for redox biology, modeling enables emergent and system level properties such 
as flux to be quantified through data fitting experiments. However obtaining this data 
depends on the generation and use of accurate kinetic models and in this regard, the analyses 
of redoxin systems (thioredoxin, glutaredoxin and peroxiredoxin) have been limited by the 
ambiguous descriptions of redoxin activity. For example, the glutaredoxin system is important 
in the glutathionylation/deglutathionylation process where protein thiols may be 
glutathionylated under oxidative stress conditions, and glutaredoxin activity is important for 
restoring the functions of these proteins (Rouhier et al., 2004, Dalle-Donne et al., 2009, 
Meyer et al., 2009). The kinetic mechanism used by glutaredoxins for deglutathionylation 
was unclear as a monothiol and a dithiol mechanism have both been proposed for 
glutaredoxin activity which complicated the modeling of this system (Pillay et al., 2013). 
Discrepancies on how peroxiredoxins should be described in computational modeling studies 
have also been identified with peroxiredoxins being characterized as enzymes, with either 
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ping-pong or mass action kinetics while in other studies peroxiredoxins have been modelled 
as redox couples (Figure 5.1). This is a central problem for redox systems biology as the 
choice of kinetic expressions for redoxins in these models can affect the models‟ properties 
and outputs for the same set of input parameters (Mashamaite et al., 2015, Padayachee and 
Pillay, 2016, Pillay et al., 2016). 
 
Similarly Trx has also been ambiguously described as both a redox couple and as an 
enzyme (Chapter 3). As the Trx system plays a critical role in several processes and is widely 
used in computational modeling experiments (Figure 5.1), it was essential to confirm the 
kinetic mechanism of this system for its application in systems biology studies. Using 
computational modeling and in vitro kinetics, it was confirmed that substrate saturation in the 
thioredoxin system was due to a limitation in the Trx redox cycle and that Michaelis-Menten 
parameters widely used to describe Trx activity are inappropriate (Chapter 3). This result was 
significant as it validated the computational and theoretical modeling approaches that have 
already modeled Trx as a redox couple (Figure 5.1).  
 
These confirmatory experiments also enabled an independent and experimentally tractable 
surrogate measure for flux to be proposed. Although data fitting experiments used for flux 
estimation are useful, it has been shown that even dissimilar computational models can fit a 
dataset. For example, in this study it was shown that the redox couple and enzyme model 
both showed excellent fits (r
2
≥0.996) to a previously published in vitro insulin reduction 
dataset (Chapter 3). Therefore having an independent measure could enable confirmation of 
the flux responses obtained from fitted models and the thioredoxin redox charge represents 
such an advance. Notably as the thioredoxin redox charge is bounded between zero and one, 
comparative analyses between conditions or cell types are possible. This may be useful in 
inhibition studies as this single measure can comparatively test the effect of several inhibitors 
of the Trx system where a decrease in the reductive thioredoxin redox charge represents a 
more effective inhibitor. Additionally, given the homology between thioredoxins, 
glutaredoxins and peroxiredoxins, this measure will encourage further theoretical and 




5.2 Future work 
In addition to the thioredoxin redox charge being used to confirm flux perturbations 
obtained from modeling experiments described above, this measure represents an 
independent and experimentally tractable approach to derive comparative quantitative 
information on the Trx system. However, before this measure can be generally accepted, in 
vivo validation is required. Once completed, this will allow for the reanalysis of thioredoxin 
redox western blotting datasets obtained from previous studies (see for example (Trotter and 
Grant, 2003, Sobhakumari et al., 2012, Ungerstedt et al., 2012)) which could lead to new 
insights into these processes. 
 
Although redox western blotting is widely used for quantifying protein redox states, this 
technique is semi-quantitative as it provides a relative comparison of protein levels, but not 
an absolute measure of quantity (Mahmood and Yang, 2012). On the other hand, ELISA 
offers several advantages compared to conventional redox western blotting including 
reproducibility and efficiency as the need for protein separation by electrophoresis is 
eliminated. The analysis of a large number of samples within a single run is also possible. 
The modification of the ELISA method (Potamitou et al., 2002, Lundberg et al., 2014, Fan et 
al., 2016) to specifically determine the thioredoxin redox charge in vitro and in vivo would be 
extremely beneficial as it can be scaled to improve throughput and therefore the role of Trx in 
pathologies can more readily be explored. However, it should be noted that several 
limitations have been associated with antibody-based methods. More than 50% of 
commercially available antibodies are of poor quality and poor validation of these antibodies 
has shown to compromise experimental results. Additionally, the secondary antibody used 
affects the signal intensity of the target protein (Gilda et al., 2015). In cases where antibodies 
cannot be produced, mass spectrometry, which has been used for the identification and 
characterization of proteins could serve as an alternate method (Clarke et al., 2016). 
   
5.3 Final remarks 
 The results presented within this thesis represent two important contributions for redox 
biology. First, the characterization of Trx activity in systems biology applications has been 
settled and provides a foundation for further systems biology analyses of the Trx network. 
Second, a novel, independent and experimentally tractable surrogate measure for flux through 
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the Trx system has been proposed and may play an important role in precisely quantifying 
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 Details of the kinetic parameters obtained for the insulin disulfide bond reduction by 
Escherichia coli and by baker‟s yeast are summarized in Table S1. 
 
Table S1: The Michaelis-Menten parameters and second-order rate constants (k2) for the 
disulfide bond reduction of insulin from computational modeling of the E. coli thioredoxin 
system and by the baker‟s yeast thioredoxin system at varying thioredoxin reductase (TR) 
concentrations. 
 













Km ± SE 
(µM) 





















0.1 34.56 ± 3.89 0.75 ± 0.02 0.02 0.989 0.02 ± 0.0001 0.997 
0.5 172.10 ± 4.24 3.88 ± 0.04 0.02 0.999 0.02 ± 0.0003 0.999 

















Km ± SE 
(µM) 





















0.05 114.64 ± 17.55 0.11 ± 0.01 0.001 0.97 0.001 ± 0.0001 
 
0.97 
0.15 77.44 ± 20.20 0.15 ± 0.01 0.002 0.92 0.002 ± 0.0003 0.94 





 Kinetic modeling experiments were carried out using the open source Python Simulator 
for Cellular Systems (PySCeS) modeling software (Olivier et al., 2005) 
(http://pysces.sourceforge.net). The following modeling files were used to analyze the E.coli 
(File 1) and the baker‟s yeast (File 2) thioredoxin systems. In these models, thioredoxin 
reductase was modeled with a two-substrate Michaelis-Menten kinetic expression and insulin 
reduction was modeled with mass-action kinetics. 
 
File 1: The PySCeS code used for modeling the E. coli thioredoxin system  
 
FIX: NADPH NADP ISS ISH 
#all data in uM, time = per second 
 
R1: NADPH + TrxSS = NADP + TrxSH 
kcat1*TR*(NADPH/Knadph)*(TrxSS/Ktrxss)/((1+NADPH/Knadph+NADP/Knadp)*(1+Trx
SS/Ktrxss)) 
     




















File 2: The PySCeS code used for modeling the baker‟s yeast thioredoxin system  
 
FIX: NADPH NADP InSH InSS 
#all data in uM, time = per second 
 
R1: NADPH + TrxSS = NADP + TrxSH 
(kcat1*TR*(NADPH/Knadph)*(TrxSS/K1trxss))/((1+NADPH/Knadph)*(1+TrxSS/K1trxss)) 
 




















The following modeling files were used to simulate a core model of the E.coli thioredoxin 
system (Pillay et al., 2011). For the incorporation of a competitive inhibitor, all the 
parameters, rates, reactions and concentrations remained the same as those seen in File 3 with 
the exception of  reaction 1 (R1) and the addition of an inhibition constant (Ki = 0.52 µM) 
(Lu et al., 2013) (File 4). 
 
File 3: The PySCeS code used for a core model of the E.coli thioredoxin system  
 
FIX: NADP NADPH H2O2 H2O PAPS PAP SO3 MetSO Met PSH PSS 
#all data in uM, time = per second 
 
R1: NADPH + TrxSS = NADP + TrxSH 
    
(kcat1*TR*(NADPH/Knadph)*(TrxSS/K1trxss))/((1+NADPH/Knadph)*(1+TrxSS/K1trxss)) 
     
R2: TrxSH + PSS = TrxSS + PSH 
    k2*TrxSH*PSS 
     
R3: MetSO + TrxSH = Met + TrxSS 
    (kcat3*MSR*MetSO*TrxSH)/(K3trxsh*MetSO+Kmetso*TrxSH+MetSO*TrxSH)     
 
R4: PAPS + TrxSH = SO3 + PAP + TrxSS 
    0.156*PAPS*TrxSH 
    
R5: H2O2 + TpxSH = H2O + TpxSS 
    k5*H2O2*TpxSH 
     
R6: TrxSH + TpxSS = TrxSS + TpxSH 
    k6*TrxSH*TpxSS 
     
#Metabolite Concentrations 
 
NADPH = 137.0 
NADP = 1.0 
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TrxSH = 1.0 
TrxSS = 1.0 
PSS = 4.23 
PSH = 1.0 
 
MetSO = 970.0 
Met = 48300.0 
PAPS = 0.07 
SO3 = 1.0 
PAP = 1.0 
H2O2 = 0.02 
H2O = 1.0 
TpxSH = 4.88 
TpxSS = 1.0 
 
#Kinetic Parameters 
TR = 4.74 
kcat1 = 22.75 
Knadph = 1.2 
K1trxss = 2.8 
k2 = 0.064 
MSR = 2.35 
kcat3 = 3.7 
Kmetso = 1900.0 
K3trxsh = 10.0 
PR = 0.345 
kcat4 = 3.5 
Kpaps = 22.5 
K4trxsh = 13.7 
k5 = 44.0 





File 4: The modified PySCeS code used for a core model of the E.coli thioredoxin system 
with the incorporation of a competitive inhibitor 
 
R1: NADPH + TrxSS = NADP + TrxSH 




The co-response analysis revealed a non-linear relationship between the reductive 
thioredoxin redox charge and the flux with increasing concentrations of NADPH and 
thioredoxin reductase (Figure 4.5). This non-linear relationship occurred as a consequence of 
the saturation of the Tpx redox cycle and therefore increasing the concentration of hydrogen 
peroxide should result in an increased demand for reduced Tpx causing an increase in the 
flux and a linear relationship between the reductive thioredoxin redox charge and the flux 
should be obtained. To test this hypothesis, co-response plots were generated with increasing 
NADPH and thioredoxin reductase concentrations as previously performed. However, the 
hydrogen peroxide concentration was increased from 0.02 µM to 20 µM (Figure S1). Under 
conditions of perturbed reductive supply, at an increased hydrogen peroxide concentration, 
the redox potential (Figure S1 A), the redox ratio (Figure S1 B) as well as the reductive 
thioredoxin redox charge (Figure S1 D) closely correlated with the flux. 
 
 
Figure S1. Co-response analysis revealed a linear relationship between the reductive 
thioredoxin redox charge and the flux when the demand for Tpx was increased. Co-
response plots were generated with varying concentrations of NADPH (-) and thioredoxin 
reductase (.-.) at a higher hydrogen peroxide concentration and the relationship with the 
redox potential (A), redox ratio (B), oxidative thioredoxin redox charge (C) and reductive 
thioredoxin redox charge (D) was determined. 
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 In addition to the plots generated using the initial linear regions within the in vitro curves 
(Figure 4.11-4.12), qualitative (Figure S2) and co-response plots (Figure S3) using the entire 





Figure S2. The reductive thioredoxin redox charge correlates with the flux as the 
reductive supply from thioredoxin reductase increased while the oxidative thioredoxin 
redox charge correlates with the flux with increasing peroxiredoxin concentrations. In 
vitro assays with varying concentrations of thioredoxin reductase and peroxiredoxin were 
performed to determine the relationship between the flux (blue) and redox potential (cyan, A 
and E), redox ratio (green, B and F), oxidative thioredoxin redox charge (red, C and G) and 










Figure S3. Co-response plots generated from in vitro assay and western blot data 
confirming that the the reductive thioredoxin redox charge correlates with the flux with 
perturbations in reductive supply and the oxidative thioredoxin redox charge correlates 
with the flux with perturbations in oxidative demand. Co-response plots were generated 
with varying concentrations of thioredoxin reductase (A-D) and peroxiredoxin (E-H) and the 
relationship with the redox potential (A and E), redox ratio (B and F), oxidative thioredoxin 




A realistic model of the red blood cell was used to determine if the proposed novel 
measure, thioredoxin redox charge was a surrogate measure for flux. The reactions included 
in the model are illustrated below (Figure S4, Table S2). The kinetic parameters and 
parameter values are given in Table S2. 
 
 
Figure S4. Reactions used to create a realistic model of hydrogen peroxide metabolism 
in human erythrocytes (Benfeitas et al., 2014). The model includes the reactions for the (i) 
generation of intracellular hydrogen peroxide from both endogenous and exogenous sources; 
(ii) hydrogen peroxide consumption via catalase, peroxiredoxin 2 and glutathione peroxidase; 
(iii) peroxiredoxin 2 sulfinylation and reduction of the sulfinic to the sulfenic form; (iv) Trx1 
oxidation by peroxiredoxin 2, reduction via thioredoxin reductase and reactions between the 
active-site dithiol and the regulatory dithiol; (v) glutathione reductase mediated reduction of 
glutathione disulfide (GSSG); and (vi) NADP
+
 reduction to NADPH by the hexose 






Table S2. Reaction rates and parameters considered in the creation of the realistic 
human erythrocyte model (Benfeitas et al., 2014). (Permission to reproduce this table was 





 A realistic model of peroxiredoxin oxidation events in S. pombe was used to determine if 
the proposed novel measure, thioredoxin redox charge was a surrogate measure for flux. The 
reactions included in the model are illustrated below (Figure S5, Table S3). The kinetic 
parameters and values are given in Table S3.  
 
 
Figure S5. Reactions used to create a realistic model of peroxiredoxin oxidation (Tpx1) 
in Schizosaccharomyces pombe upon exposure to different concentrations of  hydrogen 
peroxide (Tomalin et al., 2016). The model contains 9 Tpx1 oxidation states which are 
interconverted by the indicated reactions. The rates of hydrogen peroxide influx and efflux as 
well as the removal of hydrogen peroxide from the intracellular compartment were also 
included in the model. Permission to reproduce this figure was not required as the article was 








Table S3. Reaction parameters used in the creation of the peroxiredoxin oxidation 
model (Tomalin et al., 2016). Permission to reproduce this table was not required as the 
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